

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in primary immunodeficiency: from... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-194/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-194" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in primary immunodeficiency: from molecular diagnosis to treatment" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in primary immunodeficiency: from molecular diagnosis to treatment.">
            <meta name="og:description" content="Read the latest article version by Giorgia Bucciol, Isabelle Meyts, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="23749">
            <meta name="article-id" content="21553">
            <meta name="dc.title" content="Recent advances in primary immunodeficiency: from molecular diagnosis to treatment">
            <meta name="dc.description" content="The technological advances in diagnostics and therapy of primary immunodeficiency are progressing at a fast pace. This review examines recent developments in the field of inborn errors of immunity, from their definition to their treatment. We will summarize the challenges posed by the growth of next-generation sequencing in the clinical setting, touch briefly on the expansion of the concept of inborn errors of immunity beyond the classic immune system realm, and finally review current developments in targeted therapies, stem cell transplantation, and gene therapy.">
            <meta name="dc.subject" content="primary immunodeficiency, inborn error of immunity, next generation sequencing, targeted therapy, hematopoietic stem cell transplantation">
            <meta name="dc.creator" content="Bucciol, Giorgia">
            <meta name="dc.creator" content="Meyts, Isabelle">
            <meta name="dc.date" content="2020/03/19">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.21553.1">
            <meta name="dc.source" content="F1000Research 2020 9:194">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="primary immunodeficiency">
            <meta name="prism.keyword" content="inborn error of immunity">
            <meta name="prism.keyword" content="next generation sequencing">
            <meta name="prism.keyword" content="targeted therapy">
            <meta name="prism.keyword" content="hematopoietic stem cell transplantation">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/03/19">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="194">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.21553.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-194">
            <meta name="citation_title" content="Recent advances in primary immunodeficiency: from molecular diagnosis to treatment">
            <meta name="citation_abstract" content="The technological advances in diagnostics and therapy of primary immunodeficiency are progressing at a fast pace. This review examines recent developments in the field of inborn errors of immunity, from their definition to their treatment. We will summarize the challenges posed by the growth of next-generation sequencing in the clinical setting, touch briefly on the expansion of the concept of inborn errors of immunity beyond the classic immune system realm, and finally review current developments in targeted therapies, stem cell transplantation, and gene therapy.">
            <meta name="citation_description" content="The technological advances in diagnostics and therapy of primary immunodeficiency are progressing at a fast pace. This review examines recent developments in the field of inborn errors of immunity, from their definition to their treatment. We will summarize the challenges posed by the growth of next-generation sequencing in the clinical setting, touch briefly on the expansion of the concept of inborn errors of immunity beyond the classic immune system realm, and finally review current developments in targeted therapies, stem cell transplantation, and gene therapy.">
            <meta name="citation_keywords" content="primary immunodeficiency, inborn error of immunity, next generation sequencing, targeted therapy, hematopoietic stem cell transplantation">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Giorgia Bucciol">
            <meta name="citation_author_institution" content="Childhood Immunology, Department of Pediatrics, University Hospitals Leuven, ERN-RITA Core Member, Herestraat 49, Leuven, 3000, Belgium">
            <meta name="citation_author_institution" content="Inborn Errors of Immunity, Department of Immunology, Microbiology and Transplantation, KU Leuven, Herestraat 49, Leuven, 3000, Belgium">
            <meta name="citation_author" content="Isabelle Meyts">
            <meta name="citation_author_institution" content="Childhood Immunology, Department of Pediatrics, University Hospitals Leuven, ERN-RITA Core Member, Herestraat 49, Leuven, 3000, Belgium">
            <meta name="citation_author_institution" content="Inborn Errors of Immunity, Department of Immunology, Microbiology and Transplantation, KU Leuven, Herestraat 49, Leuven, 3000, Belgium">
            <meta name="citation_publication_date" content="2020/03/19">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="194">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.21553.1">
            <meta name="citation_firstpage" content="194">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-194/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-194.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=23749 /> <input type=hidden id=articleId name=articleId value=21553 /> <input type=hidden id=xmlUrl value="/articles/9-194/v1/xml"/> <input type=hidden id=xmlFileName value="-9-194-v1.xml"> <input type=hidden id=article_uuid value=57de6d71-b9c6-4f14-91c5-51ab5b0b2749 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in primary immunodeficiency: from molecular diagnosis to treatment"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.21553.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.21553.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-194"
  },
  "headline": "Recent advances in primary immunodeficiency: from molecular diagnosis to treatment",
  "datePublished": "2020-03-19T08:08:36",
  "dateModified": "2020-03-19T08:08:36",
  "author": [
    {
      "@type": "Person",
      "name": "Giorgia Bucciol"
    },    {
      "@type": "Person",
      "name": "Isabelle Meyts"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The technological advances in diagnostics and therapy of primary immunodeficiency are progressing at a fast pace. This review examines recent developments in the field of inborn errors of immunity, from their definition to their treatment. We will summarize the challenges posed by the growth of next-generation sequencing in the clinical setting, touch briefly on the expansion of the concept of inborn errors of immunity beyond the classic immune system realm, and finally review current developments in targeted therapies, stem cell transplantation, and gene therapy."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-194/v1",
            "name": "Recent advances in primary immunodeficiency: from molecular diagnosis..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in primary immunodeficiency: from molecular diagnosis... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=23749 data-id=21553 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21553.1" data-recommended="" data-doi="10.12688/f1000research.21553.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-194/v1/pdf?article_uuid=57de6d71-b9c6-4f14-91c5-51ab5b0b2749" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-21553-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-21553-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-21553-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bucciol G and Meyts I. Recent advances in primary immunodeficiency: from molecular diagnosis to treatment [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):194 (<a class=new-orange href="https://doi.org/10.12688/f1000research.21553.1" target=_blank>https://doi.org/10.12688/f1000research.21553.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-21553-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=21553 id=track-article-signin-21553 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21553?target=/articles/9-194/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23749 /> <input name=articleId type=hidden value=21553 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in primary immunodeficiency: from molecular diagnosis to treatment</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Giorgia Bucciol<a href="https://orcid.org/0000-0001-5004-0738" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5004-0738</div><sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:isabelle.meyts@uzleuven.be" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Isabelle Meyts</span></a><a href="https://orcid.org/0000-0003-1214-0302" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1214-0302</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Giorgia Bucciol<a href="http://orcid.org/0000-0001-5004-0738" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5004-0738</div><sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:isabelle.meyts@uzleuven.be" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Isabelle Meyts</span></a><a href="http://orcid.org/0000-0003-1214-0302" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1214-0302</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 19 Mar 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.21553.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Inborn Errors of Immunity, Department of Immunology, Microbiology and Transplantation, KU Leuven, Herestraat 49, Leuven, 3000, Belgium<br/> <sup>2</sup> Childhood Immunology, Department of Pediatrics, University Hospitals Leuven, ERN-RITA Core Member, Herestraat 49, Leuven, 3000, Belgium<br/> <p> <div class=margin-bottom> Giorgia Bucciol <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Isabelle Meyts <br/> <span>Roles: </span> Data Curation, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=65520-61377></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=65521-61378></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=65519-61376></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The technological advances in diagnostics and therapy of primary immunodeficiency are progressing at a fast pace. This review examines recent developments in the field of inborn errors of immunity, from their definition to their treatment. We will summarize the challenges posed by the growth of next-generation sequencing in the clinical setting, touch briefly on the expansion of the concept of inborn errors of immunity beyond the classic immune system realm, and finally review current developments in targeted therapies, stem cell transplantation, and gene therapy. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> primary immunodeficiency, inborn error of immunity, next generation sequencing, targeted therapy, hematopoietic stem cell transplantation </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Isabelle Meyts (<a href="mailto:isabelle.meyts@uzleuven.be">isabelle.meyts@uzleuven.be</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Isabelle Meyts </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> IM is supported by a CSL Behring Chair in Primary Immunodeficiency (paid to institution). GB declares that she has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> GB is supported by the Research Foundation - Flanders (project G0C8517N). IM is supported by the Jeffrey Modell Foundation, the Research Foundation - Flanders (project G0C8517N), and the CSL Behring Chair in Primary Immunodeficiency in Children. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Bucciol G and Meyts I. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bucciol G and Meyts I. Recent advances in primary immunodeficiency: from molecular diagnosis to treatment [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):194 (<a href="https://doi.org/10.12688/f1000research.21553.1" target=_blank>https://doi.org/10.12688/f1000research.21553.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 19 Mar 2020, <b>9</b>(F1000 Faculty Rev):194 (<a href="https://doi.org/10.12688/f1000research.21553.1" target=_blank>https://doi.org/10.12688/f1000research.21553.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 19 Mar 2020, <b>9</b>(F1000 Faculty Rev):194 (<a href="https://doi.org/10.12688/f1000research.21553.1" target=_blank>https://doi.org/10.12688/f1000research.21553.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d377e155>Introduction</h2><p class="" id=d377e158>Perhaps more than other medical disciplines, the field of primary immunodeficiency is expanding rapidly thanks to recent advances in sequencing, gene editing tools, and the introduction of new biological drugs and small molecules that target specific checkpoints relevant to immunity, inflammation, and cancer. We have witnessed, first of all, a rapid rise in the number of described monogenic inborn errors of immunity (IEIs), and more than 400 distinct defects were included in the International Union of Immunological Societies (IUIS) classification of 2019<sup><a href="#ref-1">1</a></sup>. This represents an increase of 200 new genes and diseases in 10 years and reveals a paradigm shift from “primary immunodeficiencies” as fundamental defects in the immune response to infection toward the broader concept of “inborn errors of immunity” as a comprehensive group of different phenotypes, including infection, autoinflammation, autoimmunity, allergy, and malignancy<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Indeed, a relatively new concept in IEIs is immune dysregulation caused by the innate components of immunity, in juxtaposition with adaptive immunity-driven autoimmunity. Autoinflammatory disorders are caused by an over-activation of pro-inflammatory cytokines or pathways, mostly components of the inflammasomes. They typically manifest as fevers, skin rashes, systemic inflammation, and variable arthritis and lymphadenopathy, although some forms can also present with immunodeficiency and other clinical phenotypes<sup><a href="#ref-3">3</a></sup>. A subgroup of these disorders is represented by interferonopathies, characterized by constitutively activated type I interferon (IFN) responses<sup><a href="#ref-4">4</a></sup>.</p><p class="" id=d377e180>New insight into the pathogenesis of IEIs has introduced targeted treatments next to substitution and symptomatic therapy (immunoglobulin replacement, antimicrobial and anti-inflammatory, or immunosuppressive treatments) on one side and replacement of the flawed immune system by hematopoietic stem cell transplantation (HSCT) or gene therapy on the other<sup><a href="#ref-2">2</a></sup>. Moreover, the latter have greatly benefited from the new advances in cell and gene manipulation, expanding the number of diseases to be successfully treated and increasing the survival chances of affected individuals<sup><a href="#ref-5">5</a></sup>. In this review, we focus on some of the most recent advances over the last 3 years in the diagnosis and therapy of human IEIs.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d377e194>Molecular diagnosis of inborn errors of immunity</h2><p class="" id=d377e197>Sequencing in general and next-generation sequencing (NGS) techniques in particular are becoming technically more accurate, fast, affordable and therefore widely available to researchers and physicians. Apart from the obvious result of increasing the sheer number of defined IEIs, this rapid expansion has highlighted the phenotypic heterogeneity and genetic pleiotropy of these disorders. On the other hand, many novel IEIs are studied in a single kindred or a small number of kindreds, thus providing little information on the penetrance and phenotype<sup><a href="#ref-1">1</a></sup>. Moreover, the pathophysiology often remains to be unraveled. For example, heterozygous mutations in cell division cycle 42 (<i>CDC42</i>), encoding a small GTP/GDP-binding protein involved in eukaryotic actin cytoskeleton dynamics, cause a wide range of different developmental phenotypes with or without autoinflammation, depending on the affected protein domain<sup><a href="#ref-6">6</a>–<a href="#ref-12">12</a></sup>. Patients with biallelic mutations in lariat debranching enzyme 1 (<i>DBR1</i>) have a very rare brainstem viral encephalitis through a defect of cell-intrinsic immunity that is still entirely unexplained<sup><a href="#ref-13">13</a></sup>. A relevant example of phenotypic heterogeneity is the deficiency of adenosine deaminase 2 (DADA2): originally reported as a small-vessel vasculitis manifesting with polyarteritis nodosa, livedo racemosa, stroke, and mild immunodeficiency, the phenotype has significantly expanded to include pure red cell aplasia, other cytopenias, lymphoproliferation, and lymphoma<sup><a href="#ref-14">14</a>–<a href="#ref-30">30</a></sup>.</p><p class="" id=d377e229>In at least 10 genes responsible for IEI, both gain-of-function (GOF) and loss-of-function (LOF) mutations have been described, resulting in different biological effects and clinical phenotypes (<a href="#T1">Table 1</a>)<sup><a href="#ref-31">31</a>–<a href="#ref-55">55</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. PID genes in which GOF and LOF mutations have been described.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d377e253 class=n-a></a><thead><a name=d377e255 class=n-a></a><tr><a name=d377e257 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d377e259 class=n-a></a>Protein</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e262 class=n-a></a>Gene</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e265 class=n-a></a>OMIM n.<br class=br>disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e270 class=n-a></a>Inheritance</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e273 class=n-a></a>Immunological phenotype</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e277 class=n-a></a>Infectious phenotype</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e280 class=n-a></a>Non-infectious phenotype</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e283 class=n-a></a>Autoinflammation</th><th align=left colspan=1 rowspan=1 valign=top><a name=d377e286 class=n-a></a>Therapy</th></tr></thead><tbody><a name=d377e291 class=n-a></a><tr><a name=d377e293 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d377e295 class=n-a></a>STAT1</td><td align=left colspan=1 rowspan=3 valign=top><a name=d377e298 class=n-a></a><i>STAT1</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e302 class=n-a></a>613796</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e305 class=n-a></a>AR<br class=br>Complete/partial LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e310 class=n-a></a>Deficient intracellular<br class=br>pathogen killing by<br class=br>monocytes and T cells;<br class=br>impaired IFN type I<br class=br>response to viral infections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e322 class=n-a></a>Lethal viral diseases and<br class=br>susceptibility to mycobacterial<br class=br>infection</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e329 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e332 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e335 class=n-a></a>N/A</td></tr><tr><a name=d377e339 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e341 class=n-a></a>614892</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e344 class=n-a></a>AD<br class=br>Dominant-negative<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e351 class=n-a></a>Deficient intracellular<br class=br>pathogen killing by<br class=br>monocytes and T cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e358 class=n-a></a>Mendelian susceptibility to<br class=br>mycobacterial disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e363 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e367 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e370 class=n-a></a>IFN-γ</td></tr><tr><a name=d377e374 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e376 class=n-a></a>614162</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e379 class=n-a></a>AD<br class=br>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e384 class=n-a></a>Low Th17 proportions<br class=br>± low memory B cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e389 class=n-a></a>Chronic mucocutaneous<br class=br>candidiasis, bacterial and<br class=br>viral infections, invasive fungal<br class=br>infections, mycobacterial<br class=br>disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e400 class=n-a></a>Intracranial aneurysms,<br class=br>autoimmunity, enteropathy,<br class=br>bronchiectasis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e408 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e411 class=n-a></a>JAK inhibitor<br class=br>(ruxolitinib)<br class=br>HSCT</td></tr><tr><a name=d377e419 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d377e421 class=n-a></a>CARD11</td><td align=left colspan=1 rowspan=3 valign=top><a name=d377e424 class=n-a></a><i>CARD11</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e428 class=n-a></a>615206</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e431 class=n-a></a>AR<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e436 class=n-a></a>Defective NF-κB signaling<br class=br>with B- and T-cell<br class=br>functional impairment,<br class=br>hypogammaglobulinemia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e446 class=n-a></a><i>Pneumocystis jirovecii</i><br class=br>pneumonia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e452 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e455 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e458 class=n-a></a>HSCT</td></tr><tr><a name=d377e462 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e464 class=n-a></a>617638</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e467 class=n-a></a>AD<br class=br>Dominant-negative<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e474 class=n-a></a>Defects in T-cell activation,<br class=br>increased IgE, and<br class=br>eosinophilia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e481 class=n-a></a>Recurrent or severe infections,<br class=br>including pneumonia,<br class=br>molluscum, abscesses, and<br class=br>bacteremia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e490 class=n-a></a>Moderate to severe<br class=br>atopic dermatitis, asthma,<br class=br>allergies, ulcerative colitis,<br class=br>T-cell lymphoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e500 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e503 class=n-a></a>N/A</td></tr><tr><a name=d377e508 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e510 class=n-a></a>616452</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e513 class=n-a></a>AD<br class=br>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e518 class=n-a></a>B-cell expansion with<br class=br>NF-κB and T-cell anergy<br class=br>(BENTA), decreased T-cell<br class=br>proliferative responses and<br class=br>vaccine responses</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e529 class=n-a></a>Recurrent upper respiratory<br class=br>infections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e534 class=n-a></a>Splenomegaly,<br class=br>lymphadenopathy,<br class=br>autoimmunity, chronic<br class=br>lymphocytic leukemia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e544 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e547 class=n-a></a>N/A</td></tr><tr><a name=d377e551 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e553 class=n-a></a>WASP</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e556 class=n-a></a><i>WAS</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e560 class=n-a></a>301000</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e563 class=n-a></a>X-linked recessive<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e568 class=n-a></a>Lymphopenia,<br class=br>hypogammaglobulinemia,<br class=br>eosinophilia, decreased<br class=br>vaccine responses</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e578 class=n-a></a>Recurrent bacterial infections, molluscum</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e581 class=n-a></a>Microthrombocytopenia,<br class=br>eczema, autoimmunity,<br class=br>hematological<br class=br>malignancies, inflammatory<br class=br>bowel disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e592 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e595 class=n-a></a>HSCT, gene<br class=br>therapy</td></tr><tr><a name=d377e601 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e603 class=n-a></a>300299</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e606 class=n-a></a>X-linked recessive<br class=br>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e611 class=n-a></a>Severe congenital<br class=br>neutropenia,<br class=br>monocytopenia, natural<br class=br>killer cell deficiency,<br class=br>increased CD8<sup>+</sup> T cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e625 class=n-a></a>Severe bacterial infections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e628 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e632 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e635 class=n-a></a>Granulocyte-<br class=br>colony-<br class=br>stimulating<br class=br>factor</td></tr><tr><a name=d377e645 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e647 class=n-a></a>MDA5</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e650 class=n-a></a><i>IFIH1</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e654 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e657 class=n-a></a>AR/AD<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e662 class=n-a></a>Respiratory epithelial cells<br class=br>and fibroblasts</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e668 class=n-a></a>Rhinovirus and other<br class=br>respiratory viral infections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e673 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e676 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e679 class=n-a></a>N/A</td></tr><tr><a name=d377e683 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e685 class=n-a></a>615846</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e688 class=n-a></a>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e691 class=n-a></a>Aicardi–Goutieres<br class=br>syndrome: type I<br class=br>interferonopathy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e698 class=n-a></a>Not reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e701 class=n-a></a>Pseudo-TORCH<br class=br>syndrome: basal ganglia<br class=br>calcification, microcephaly,<br class=br>developmental delay,<br class=br>spasticity, autoimmunity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e713 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e716 class=n-a></a>JAK inhibitor<br class=br>(ruxolitinib)</td></tr><tr><a name=d377e722 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e724 class=n-a></a>STAT3</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e727 class=n-a></a><i>STAT3</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e731 class=n-a></a>147060</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e734 class=n-a></a>AD<br class=br>Dominant-negative<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e741 class=n-a></a>Hyper IgE syndrome,<br class=br>eosinophilia, T-cell defect<br class=br>with Th17 deficiency,<br class=br>decreased vaccine<br class=br>responses</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e753 class=n-a></a>Recurrent Staphylococcal<br class=br>infections, fungal infections,</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e758 class=n-a></a>Coarse facial appearance,<br class=br>abnormal dentition,<br class=br>hyperextensibility of the<br class=br>joints, and bone fractures</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e767 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e770 class=n-a></a>HSCT?</td></tr><tr><a name=d377e775 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e777 class=n-a></a>615952</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e780 class=n-a></a>AD<br class=br>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e785 class=n-a></a>T-cell lymphopenia,<br class=br>hypogammaglobulinemia,<br class=br>increased double-negative<br class=br>T cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e794 class=n-a></a>Recurrent infections, including<br class=br>fungal infections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e799 class=n-a></a>Autoimmunity, dermatitis,<br class=br>arthritis, interstitial lung<br class=br>disease, short stature,<br class=br>lymphadenopathy,<br class=br>splenomegaly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e811 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e814 class=n-a></a>HSCT?</td></tr><tr><a name=d377e818 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e820 class=n-a></a>STAT2</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e823 class=n-a></a><i>STAT2</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e827 class=n-a></a>616636</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e830 class=n-a></a>AR<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e835 class=n-a></a>Defective type I IFN-STAT<br class=br>signaling</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e841 class=n-a></a>Increased susceptibility to viral<br class=br>infections and to disseminated<br class=br>disease after live vaccines<br class=br>(measles)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e850 class=n-a></a>Defect of mitochondrial<br class=br>fission and fusion</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e855 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e858 class=n-a></a>N/A</td></tr><tr><a name=d377e862 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e864 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e867 class=n-a></a>AR<br class=br>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e872 class=n-a></a>Type I interferonopathy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e875 class=n-a></a>Not reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e878 class=n-a></a>Severe early-onset<br class=br>autoinflammation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e884 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e887 class=n-a></a>N/A (possibly<br class=br>JAK inhibitor)</td></tr><tr><a name=d377e893 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e895 class=n-a></a>Complement<br class=br>factor B</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e900 class=n-a></a><i>CFB</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e904 class=n-a></a>615561</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e907 class=n-a></a>AR<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e912 class=n-a></a>Inactive alternative<br class=br>complement pathway</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e918 class=n-a></a>Infections with encapsulated<br class=br>bacteria</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e923 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e926 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e929 class=n-a></a>Vaccination,<br class=br>prophylactic<br class=br>antibiotics</td></tr><tr><a name=d377e937 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e939 class=n-a></a>612924</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e942 class=n-a></a>AD<br class=br>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e947 class=n-a></a>Decreased C3 and<br class=br>increased C3b</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e952 class=n-a></a>Not reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e955 class=n-a></a>Atypical hemolytic uremic<br class=br>syndrome</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e961 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e964 class=n-a></a>N/A</td></tr><tr><a name=d377e968 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e970 class=n-a></a>C3</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e973 class=n-a></a><i>C3</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e977 class=n-a></a>613779</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e980 class=n-a></a>AR<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e985 class=n-a></a>C3 deficiency</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e989 class=n-a></a>Recurrent bacterial infections,<br class=br>mainly by Gram-negative<br class=br>bacteria</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e996 class=n-a></a>Immune complex-mediated<br class=br>autoimmune disease,<br class=br>glomerulonephritis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1003 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1006 class=n-a></a>N/A</td></tr><tr><a name=d377e1011 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1013 class=n-a></a>612925</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1016 class=n-a></a>AD<br class=br>GOF/LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1021 class=n-a></a>None</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1024 class=n-a></a>Not reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1027 class=n-a></a>Atypical hemolytic uremic<br class=br>syndrome</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1033 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1036 class=n-a></a>N/A</td></tr><tr><a name=d377e1040 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e1042 class=n-a></a>JAK1</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e1045 class=n-a></a><i>JAK1</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1049 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1052 class=n-a></a>AR<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1057 class=n-a></a>Progressive T-cell<br class=br>lymphopenia, increased<br class=br>IgG</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1065 class=n-a></a>Mendelian susceptibility to<br class=br>mycobacterial disease, warts,<br class=br>parasitic and fungal infections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1072 class=n-a></a>Early-onset bladder<br class=br>carcinoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1077 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1080 class=n-a></a>N/A</td></tr><tr><a name=d377e1084 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1086 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1089 class=n-a></a>AD<br class=br>GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1094 class=n-a></a>Eosinophilia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1097 class=n-a></a>Not reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1100 class=n-a></a>Hepatosplenomegaly,<br class=br>liver cysts, severe atopic<br class=br>dermatitis, allergy,<br class=br>autoimmunity, failure to<br class=br>thrive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1112 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1115 class=n-a></a>JAK inhibitor<br class=br>(ruxolitinib)</td></tr><tr><a name=d377e1121 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d377e1123 class=n-a></a>ZAP70</td><td align=left colspan=1 rowspan=2 valign=top><a name=d377e1126 class=n-a></a><i>ZAP70</i></td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1130 class=n-a></a>269840</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1133 class=n-a></a>AR<br class=br>LOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1138 class=n-a></a>Selective T-cell defect with<br class=br>CD8<sup>+</sup> deficiency and CD4<sup>+</sup><br class=br>impairment</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1151 class=n-a></a>Severe combined<br class=br>immunodeficiency phenotype:<br class=br>bacterial, viral and<br class=br>opportunistic infections</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1160 class=n-a></a>N/A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1163 class=n-a></a>No</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1166 class=n-a></a>HSCT</td></tr><tr><a name=d377e1170 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1172 class=n-a></a>617006</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1175 class=n-a></a>AR<br class=br>LOF + GOF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1180 class=n-a></a>Mild T- and B-cell<br class=br>lymphopenia, reduced<br class=br>CD8<sup>+</sup> T cells, decreased<br class=br>T-cell proliferative<br class=br>responses</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1194 class=n-a></a>Not reported</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1197 class=n-a></a>Bullous pemphigoid,<br class=br>inflammatory bowel<br class=br>disease, autoimmunity</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1205 class=n-a></a>Yes</td><td align=left colspan=1 rowspan=1 valign=top><a name=d377e1208 class=n-a></a>HSCT</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d377e1216 class=n-a></a><p id=d377e1218> AD, autosomal dominant; AR, autosomal recessive; GOF, gain of function; HSCT, hematopoietic stem cell transplantation; IFN, interferon; JAK, Janus kinase; LOF, loss of function; N/A, not available/not applicable; NF-κB, nuclear factor kappa B; STAT, signal transducer and activator of transcription; Th, T helper; TORCH, toxoplasmosis, rubella, cytomegalovirus, herpes.</p></div></div></div><p class="" id=d377e1224>Mutations of signal transducer and activator of transcription 1 (<i>STAT1</i>) are exemplary. Biallelic LOF mutations cause either complete or partial STAT1 deficiency: the first impairs type I and II IFN responses and produces a severe phenotype of mycobacterial and viral susceptibility, which invariably is fatal if not corrected by HSCT; the second has a similar but milder presentation<sup><a href="#ref-46">46</a>,<a href="#ref-47">47</a>,<a href="#ref-56">56</a>–<a href="#ref-60">60</a></sup>. Heterozygous mutations with a dominant-negative LOF effect impair mainly type II IFN signaling and cause mendelian susceptibility to mycobacterial disease (MSMD) and salmonellosis<sup><a href="#ref-48">48</a>,<a href="#ref-57">57</a>,<a href="#ref-61">61</a></sup>. Finally, heterozygous <i>STAT1</i> GOF mutations affect interleukin-17 (IL-17) immunity and cause autosomal dominant (AD) chronic mucocutaneous candidiasis (CMC), bacterial and viral infections, autoimmunity, and cerebral aneurysms<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a>,<a href="#ref-57">57</a>,<a href="#ref-62">62</a></sup>. A similar situation can be seen in defects of caspase recruitment domain family 11 (<i>CARD11</i>). Homozygous null mutations in fact cause a profound combined immunodeficiency, heterozygous dominant-negative LOF mutations cause combined immunodeficiency with severe atopic disease, and heterozygous GOF mutations instead cause B-cell expansion with nuclear factor kappa B (NF-κB) and T-cell anergy (BENTA) disease<sup><a href="#ref-51">51</a>–<a href="#ref-55">55</a>,<a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. These examples of additional phenotypes progressively connected to different mutations in the same genes highlight the risk of labeling heterozygous variants as irrelevant to the observed clinical phenotype without functional testing.</p><p class="" id=d377e1287>With NGS methods routinely available for diagnosis and with a shift from the fixed gene panel and whole exome sequencing (WES) toward whole genome sequencing (WGS), we also learned that deep intronic variants can be disease-causing<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. For example, various deep intronic mutations in <i>UNC13D</i>, underlying familial hemophagocytic lymphohistiocytosis (HLH), are very commonly found in patients of European, North American, or Asian origin<sup><a href="#ref-67">67</a>–<a href="#ref-71">71</a></sup>. Similarly, intronic mutations were found in a number of IEI-causing genes: in <i>IL7R</i> and Janus kinase 3 (<i>JAK3</i>) in patients with severe combined immunodeficiency (SCID); in <i>ZAP70</i>, encoding the zeta chain-associated protein kinase, in a child with severe T-cell immunodeficiency; in <i>STAT3</i> in a patient with hyper IgE syndrome; in the NF-κB essential modulator (<i>NEMO</i>) in two patients with ectodermal dysplasia and immunodeficiency (EDA-ID); in <i>POLA1</i>, encoding DNA polymerase α, in patients with X-linked recessive reticulate pigmentary disorder (XLPDR); in <i>CYBB</i>, encoding p91-PHOX, in patients with chronic granulomatous disease (CGD); in <i>ATM</i> in patients with ataxia-telangiectasia; and in <i>CD40LG</i> in patients with hyper IgM syndrome<sup><a href="#ref-72">72</a>–<a href="#ref-85">85</a></sup>. RNA sequencing can be an invaluable tool in the validation of these deep intronic variants but also of synonymous and splice-site variants<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a>,<a href="#ref-86">86</a>,<a href="#ref-87">87</a></sup>. In particular, it can highlight the partial or complete loss of gene expression in the proband compared with controls, which would be missed by traditional sequencing. The increase in diagnostic rate of rare diseases obtained by WGS versus WES can be as high as 6 to 11%, and the use of tissue-specific RNA sequencing can aid the diagnostic process and help clarify the pathophysiology of the disease<sup><a href="#ref-86">86</a>,<a href="#ref-87">87</a></sup>. Interestingly, in the case of monogenic rare diseases, RNA sequencing as the first molecular approach led to a diagnosis in 7 to 17% of cases<sup><a href="#ref-87">87</a></sup>. No hematological/immunological disorders were among those successfully diagnosed in this cohort, which consisted mostly of patients affected by neuromuscular disorders. A lower success rate in IEIs could also be a reflection of the difficulty of comparing normal controls with patients with significant blood cell abnormalities.</p><p class="" id=d377e1367>The benefit of diagnostic NGS comes at a cost: the necessity of unequivocal functional validation of new variants, albeit in known IEI-related genes. Still too often the pathogenicity of a given variant is based only on the available <i>in silico</i> prediction tools, which can be misleading. Indeed, the validation of variants of unknown significance represents one of the biggest hurdles in making WES and NGS technologies the norm in clinical practice. This is because of not only the financial cost but also the time and competence required first to analyze and study a variant and afterwards to interpret the results and translate them into clinical treatment and care. More than anything, this calls for collaboration and sharing of data for the benefit of the patients. With limited research resources, the further development of more robust prediction tools/validation models becomes a necessity. Finally, as physician-scientists, we wish to stress the importance of the clinical phenotype as a beacon in the era of so-called unbiased sequencing approaches.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d377e1376>Inborn errors of immunity in other diseases</h2><p class="" id=d377e1379>As previously mentioned, the concept of what constitutes an immunodeficiency is steadily shifting from a focus on defects of hematopoietic immune system components, such as leukocytes and immunoglobulins, to conditions affecting immunity at the organism level<sup><a href="#ref-88">88</a></sup>. Classic examples are cystic fibrosis and sickle cell disease: the first is a chloride channel defect with primarily pulmonary and digestive manifestations, the second is a red blood cell disease caused by mutations in the β-globin gene, and both have recurrent and life-threatening infections as major symptoms (secondary to functional asplenia in the case of sickle cell disease)<sup><a href="#ref-88">88</a>–<a href="#ref-93">93</a></sup>. All cells and tissues exert essential host defense functions that range from physical and chemical barriers to pathogen sensing, cytokine production, and protein secretion and activation of the immune response upon infection, representing cell-intrinsic immunity. Infection and inflammation in fact can arise in several disorders of organs other than the classic hematopoietic immune system. The importance of these cell-specific immune responses is apparent when we consider those IEI characterized by the involvement of a single non-hematopoietic tissue, such as the central nervous system (CNS)-specific lack of resistance against herpesviruses in case of mutations of the Toll-like receptor 3/IFN pathway, or the keratinocyte-restricted susceptibility to beta-papillomavirus infections in epidermodysplasia verruciformis (due to null mutations in transmembrane channel-like protein 6 [<i>TMC6</i>], <i>TMC8</i> [encoding EVER1 and EVER2, respectively], or <i>CIB1</i>, encoding calcium- and integrin-binding protein 1)<sup><a href="#ref-94">94</a>–<a href="#ref-104">104</a></sup>. More generally, inherited defects of the skin or mucosal barriers cause at the very least a detrimental secondary effect on immune protection, as well exemplified by genodermatoses and inflammatory bowel diseases.</p><p class="" id=d377e1410>Several defects of the skin barrier frequently cause secondary infection of the affected epithelia and can also present with additional features resembling known IEIs<sup><a href="#ref-105">105</a></sup>, such as Netherton syndrome (caused by autosomal recessive [AR] defects in <i>SPINK5</i>), hyper IgE syndrome (caused by defects in <i>STAT3</i>, <i>DOCK8</i>, <i>IL6ST</i>, <i>ZNF341</i>, or phosphoglucomutase 3 [<i>PGM3</i>]), or immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome (caused by X-linked <i>FOXP3</i> defects). Defects in desmoglein 1 (DSG1) or desmoplakin (DSP), structural desmosomal proteins, cause severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome, a severe multisystemic disease resembling IPEX syndrome at least clinically<sup><a href="#ref-106">106</a>,<a href="#ref-107">107</a></sup>. Recent reports have highlighted the complex clinical and immunological phenotype of this disease, including recurrent sepsis and mucocutaneous HSV-1 infection in a patient and T helper 1 (Th1)/Th17/IL-23 skewing in the skin and Th17/IL-22 skewing in the blood of another patient, which merit further research<sup><a href="#ref-108">108</a>–<a href="#ref-110">110</a></sup>.</p><p class="" id=d377e1453>The immunological effects of glycosylation defects and metabolic diseases have also recently gained interest in the IEI field. Glycosylation is crucial in many mechanisms of the immune response, such as pathogen recognition and cell–cell interaction, and glycoimmunology is a rapidly expanding field of research<sup><a href="#ref-111">111</a>–<a href="#ref-119">119</a></sup>. Among the currently known congenital disorders of glycosylation (CDGs) (around 133 heterogenous diseases), 23 show a relevant degree of immune impairment; in 10 of these, immunodeficiency is a prominent trait of the disease<sup><a href="#ref-118">118</a></sup>. Two of these CDGs manifest as severe congenital neutropenia caused by defects in Jagunal homolog 1 (<i>JAGN1</i>) and glucose-6-phosphatase catalytic 3 (<i>G6PC3</i>), one is a leukocyte adhesion deficiency type II due to defects in solute carrier family 35 member C1 (<i>SLC35C1</i>), one is a glycogen storage disease type I with neutropenia or neutrophil dysfunction (or both) caused by defects in <i>SLC37A4</i>, and the others show various degrees of lymphocyte and immunoglobulin impairment<sup><a href="#ref-118">118</a>,<a href="#ref-120">120</a>–<a href="#ref-125">125</a></sup>. Additionally, AR <i>PGM3</i> mutations cause glycosylation defects that lead to atopy, immune deficiency with hyper IgE, autoimmunity, and neurocognitive impairment<sup><a href="#ref-126">126</a></sup>. Finally, a recent study highlighted the role of impaired glycosylation in the pathogenesis of X-linked immunodeficiency with magnesium defect, Epstein–Barr virus (EBV) infection, and neoplasia (XMEN) disease, caused by hemizygous LOF mutations in the magnesium transporter 1 (<i>MAGT1</i>) gene<sup><a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup>. On the other side, the study of differentially glycosylated antibodies and their diverse antigen reactivity will teach us more about the fine tuning of the immune responses by glycosylation<sup><a href="#ref-129">129</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d377e1515>Targeted therapies for inborn errors of immunity</h2><p class="" id=d377e1518>Recent developments in molecular studies have allowed the identification of several possible targets for specific therapeutic interventions. Targeted therapies comprise monoclonal antibodies (mAbs) and small molecules, such as cytokines or cytokine inhibitors, employed to up- or down-regulate a particular pathway, depending on the need. They can be used instead of or in combination with traditional immunosuppressant/immunomodulating agents, also as a bridge to definitive treatment, such as HSCT or gene therapy. Well-known targeted therapies are rituximab (anti-CD20) to treat autoimmune and lymphoproliferative manifestations; enzyme replacement therapy with pegylated bovine adenosine deaminase (ADA) to treat ADA-SCID; IFN-γ to increase superoxide production in the monocytes/macrophages of patients with CGD and to enhance anti-mycobacterial immunity in patients with defects of the IFN-γ/IL-12R pathway; anti-tumor necrosis factor alpha (anti-TNFα) to treat defects of the immunoproteasome causing an autoinflammatory syndrome; IL-1 signal antagonists to treat inflammasome disorders; and finally mechanistic target of rapamycin (mTOR) inhibitors to control aberrant proliferation of effector T cells in various immune dysregulation disorders, such as in IPEX, or to downregulate increased mTOR signaling, such as in activated phosphoinositide 3-kinase δ (PI3Kδ) syndrome (APDS, or PASLI)<sup><a href="#ref-130">130</a>–<a href="#ref-136">136</a></sup>.</p><p class="" id=d377e1528>The latest molecular defects to be targeted in the context of IEI therapy are <i>PI3Kδ</i> activating mutations, cytotoxic T lymphocyte-associated antigen 4 (<i>CTLA4</i>) haploinsufficiency and the closely related lipopolysaccharide (LPS)-responsive beige-like anchor (<i>LRBA</i>) deficiency, <i>STAT1</i> GOF mutations, <i>STAT3</i> GOF mutations, IFN-γ activation in the context of HLH, and activating defects in NLR family CARD domain-containing 4 (<i>NCLR4</i>).</p><div class=section><a name=d377e1550 class=n-a></a><h3 class=section-title>Selective inhibitors of PI3Kδ</h3><p class="" id=d377e1555>Patients with APDS present with recurrent respiratory tract infections, herpesvirus infections, lymphoproliferation, autoimmunity and a characteristic immunophenotype with impaired class-switch recombination, hypogammaglobulinemia, T-cell hyperactivation, and senescence with loss of naïve T cells and predominance of CD8<sup>+</sup> cells<sup><a href="#ref-136">136</a>–<a href="#ref-142">142</a></sup>. Two selective PI3Kδ inhibitors have been tested on patients with APDS: Leniolisib, a potent oral inhibitor of the p110δ subunit of PI3Kδ (ClinicalTrials.gov Identifier: NCT02435173), has shown significant effects on general well-being, lymphoproliferation, and immunological markers, such as normalization of B-cell subsets, reduction of senescent T cells, and reduction of IgM and of inflammatory cytokines<sup><a href="#ref-143">143</a>,<a href="#ref-144">144</a></sup>. Nemiralisib, an inhaled PI3Kδ inhibitor (ClinicalTrials.gov Identifier: NCT02593539), could benefit patients primarily affected by airway infection and bronchiectasis and is being trialed in patients with APDS<sup><a href="#ref-145">145</a></sup>.</p></div><div class=section><a name=d377e1580 class=n-a></a><h3 class=section-title>CTLA4-IgG fusion proteins</h3><p class="" id=d377e1585>CTLA4 haploinsufficiency causes impaired T-cell suppressor function, CD4<sup>+</sup> T-cell deficiency, progressive loss of B cells, and increase in autoreactive B cells. Clinical manifestations are recurrent sinopulmonary and viral infections, severe autoimmunity with cytopenia, lymphocytic interstitial lung disease, enteropathy, colitis, and lymphoproliferation with lymphocytic infiltration of solid organs, such as the brain and endocrine glands<sup><a href="#ref-146">146</a>–<a href="#ref-148">148</a></sup>. Although the pathophysiology of LRBA deficiency is still incompletely elucidated, LRBA acts a chaperone protein for CTLA4 to allow its recycling in endosomes. LRBA deficiency causes increased degradation of CTLA4 and a combined immunodeficiency disorder with hypogammaglobulinemia, infections, and severe autoimmune features, including cytopenias, enteropathy, lymphoproliferation, hepatitis, diabetes, polyarthritis, and alopecia<sup><a href="#ref-149">149</a>–<a href="#ref-151">151</a></sup>. CTLA4-IgG fusion proteins abatacept and belatacept have demonstrated significant results in restoring the impaired checkpoint balance and reducing symptoms in CTLA4- and LRBA-deficient patients. In particular, they could restore regulatory T (Treg) cell function and halt or (partially) resolve autoimmune, lymphoproliferative, and inflammatory symptoms, including interstitial lung disease, enteropathy, cytopenias, and other autoimmune manifestations<sup><a href="#ref-148">148</a>,<a href="#ref-152">152</a>–<a href="#ref-154">154</a></sup>.</p></div><div class=section><a name=d377e1617 class=n-a></a><h3 class=section-title>JAK/STAT inhibitors (Jakinibs)</h3><p class="" id=d377e1622>GOF mutations in <i>STAT1</i> cause CMC, bacterial and viral infections, autoimmunity, immune dysregulation, and a higher risk of cerebral aneurysms and vasculopathy<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a>,<a href="#ref-62">62</a></sup>. STAT1 is a signal transducer downstream from type I and II IFN receptors and other cytokine receptors, such as IL-21R and IL-2R. GOF defects in <i>STAT3</i> cause a severe autoimmune syndrome with growth impairment, lymphoproliferation, and inflammatory features<sup><a href="#ref-33">33</a>,<a href="#ref-155">155</a>,<a href="#ref-156">156</a></sup>. STAT3 also signals downstream from type I, II, and III IFN receptors, IL-10R, IL-23R, and IL-6R. These receptors activate STAT1 and STAT3 through JAK proteins (JAK1, JAK2, and JAK3), thus initiating the transcription of several factors relevant to the immune response, cell proliferation, differentiation, and survival. Jakinibs are small molecules that inhibit the signal transduction through JAK proteins: tofacitinib preferentially inhibits JAK1 and JAK3, ruxolitinib and baricitinib inhibit JAK1 and JAK2, and many other Jakinibs with different JAK specificity were recently discovered<sup><a href="#ref-157">157</a>,<a href="#ref-158">158</a></sup>. Ruxolitinib and tofacitinib have been used in patients with STAT1 or STAT3 GOF mutations, mostly with significant clinical improvement on fungal infections, autoimmune manifestations, and lymphoproliferation<sup><a href="#ref-159">159</a>–<a href="#ref-164">164</a></sup>. Selective inhibition of IL-6R with tocilizumab is also a valid targeted therapy in STAT3 GOF defects, especially when combined with Jakinibs<sup><a href="#ref-155">155</a>,<a href="#ref-159">159</a></sup>.</p></div><div class=section><a name=d377e1674 class=n-a></a><h3 class=section-title>Anti-IFN-γ mAb</h3><p class="" id=d377e1679>HLH is a disease characterized by hyperinflammation and immune dysregulation and is fatal if not treated. It can be primary, owing to defects of cytotoxic T cells, natural killer (NK) cells, or genes required for EBV control and clearance, or secondary, owing to an exaggerated response to viral infections, malignancies, or rheumatologic disorders. Its manifestations are fever, systemic inflammation, splenomegaly, cytopenias, and hemophagocytosis in the bone marrow, with or without CNS involvement. Isolated CNS forms have also been described<sup><a href="#ref-165">165</a></sup>. Classic treatment targets the life-threatening inflammation and includes steroid therapy, chemotherapy (etoposide and intrathecal methotrexate), and HSCT<sup><a href="#ref-166">166</a>,<a href="#ref-167">167</a></sup>. Anti-CD52 mAb alemtuzumab has been proven effective as salvage therapy of refractory HLH<sup><a href="#ref-168">168</a></sup>. Emapalumab is a recently developed mAb against IFN-γ and has been tested for treatment of HLH. An international phase II/III trial (ClinicalTrials.gov Identifier: NCT01818492) showed a good safety profile and efficacy, an overall response rate of 65%, and a complete response in 26% of cases<sup><a href="#ref-169">169</a>,<a href="#ref-170">170</a></sup>. However, caution is warranted as the number of patients who have received treatment is still very small and the concomitant therapies were significant.</p></div><div class=section><a name=d377e1705 class=n-a></a><h3 class=section-title>Future applications</h3><p class="" id=d377e1710>Treatment with Jakinibs could benefit other disorders characterized by inflammation and hyperactivation of the IFN pathways, such as interferonopathies, stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy, and HLH<sup><a href="#ref-171">171</a>–<a href="#ref-173">173</a></sup>. Ruxolitinib was recently used in two patients with HLH: both showed a decrease of inflammatory markers, but only one recovered from cytopenias and survived long enough to receive HSCT<sup><a href="#ref-174">174</a>,<a href="#ref-175">175</a></sup>. A phase I trial evaluating ruxolitinib for patients with HLH is now recruiting (ClinicalTrials.gov Identifier: NCT02400463).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d377e1731>Recent advances in hematopoietic stem cell transplantation and gene therapy</h2><p class="" id=d377e1734>Since they are largely due to intrinsic defects of hematopoietic cells or their descendant, the mature blood cells, HSCT represents the treatment of choice for many IEIs. Thanks to better and faster molecular diagnosis, improvement in conditioning practices, better donor selection and graft manipulation, and development of more successful supportive therapies to guarantee engraftment while fending off infections and graft-versus-host disease (GvHD), the overall survival of immunodeficient patients after HSCT has steadily improved up to over 80%<sup><a href="#ref-176">176</a>–<a href="#ref-179">179</a></sup>. What then are the challenges and future perspectives in this field?</p><div class=section><a name=d377e1744 class=n-a></a><h3 class=section-title>Newborn screening and hematopoietic stem cell transplantation</h3><p class="" id=d377e1749>Newborn screening has changed the landscape of HSCT for SCID because early diagnosis allows early transplantation with a smaller burden of infection. Based on a T-cell receptor excision circle assay performed on the dried blood spots taken after birth for the other newborn screenings, it has been extensively (though not uniformly) adopted in Europe and the US in the last decade<sup><a href="#ref-180">180</a>,<a href="#ref-181">181</a></sup>. It allows the identification of T-cell development disorders that affect the diversity of T-cell receptor recombination, namely SCIDs. Although there is no consensus about the influence of the diagnostic method on overall survival, HSCT before the age of 3.5 months is associated with fewer infectious complications and higher survival, and event-free survival is better for children identified by newborn screening if uninfected at the time of transplant<sup><a href="#ref-182">182</a>–<a href="#ref-184">184</a></sup>. Indeed, the current challenge lies in protecting SCID babies identified by newborn screening from infection prior to transplantation. Early diagnosis of SCID also poses therapeutic dilemmas: while owing to the high risk of infections delaying HSCT is not recommended, there are no data on long-term neurotoxicity of conditioning regimens in young infants. Moreover, the genetic diagnosis may not be available in time to adapt the transplantation plan accordingly, and patients with radiosensitive SCIDs such as Artemis or DNA ligase IV deficiency could experience severe early toxicity and long-term sequelae after standard conditioning since chemotherapy causes DNA breakages in non-hematopoietic cells and tissues.</p></div><div class=section><a name=d377e1767 class=n-a></a><h3 class=section-title>Conditioning</h3><p class="" id=d377e1772>Although the level of chimerism needed to correct IEIs is not precisely defined, most IEIs do not require full donor chimerism, explaining why modified myeloablative and reduced intensity conditioning has become the practice of choice in many centers to reduce acute and long-term toxicity<sup><a href="#ref-185">185</a></sup>. A promising line of research is represented by targeted antibody-based conditioning strategies, which are probably going to replace chemotherapy-based regimens in the near future<sup><a href="#ref-186">186</a></sup>. These therapeutic agents work by selectively targeting bone marrow cells and leukocytes for apoptosis, either by disrupting the physiological cell proliferation/cell death cycle or by delivering a radioisotope or a drug toxic to the cell. CD45 (or common leukocyte antigen) is selectively expressed on hematopoietic cells. Rat anti-CD45 mAbs were used together with anti-CD52 (alemtuzumab) and cyclophosphamide in a small group of patients with IEIs and pre-existing organ toxicity with good outcome<sup><a href="#ref-187">187</a></sup>. Further trials of radioisotope-labeled anti-CD45 mAb are ongoing in patients with myeloid disorders (ClinicalTrials.gov Identifiers: NCT00119366 and NCT01300572), and antibody–drug conjugates have shown promising results in several animal models<sup><a href="#ref-188">188</a>–<a href="#ref-192">192</a></sup>. Similarly, a mAb against CD117 (or c-Kit), necessary for survival, proliferation, and differentiation of hematopoietic stem cells and early progenitors, has demonstrated good preclinical results in animal models and is being tested in patients with SCID (ClinicalTrials.gov Identifier: NCT02963064)<sup><a href="#ref-193">193</a>–<a href="#ref-195">195</a></sup>.</p></div><div class=section><a name=d377e1802 class=n-a></a><h3 class=section-title>Gene therapy</h3><p class="" id=d377e1807>Hematopoietic stem cells are the perfect candidate for genetic manipulation. Indeed, gene therapy has been applied to the treatment of blood-specific disorders, including IEIs, for at least three decades<sup><a href="#ref-196">196</a></sup>. The first attempts at gene therapy in the field of IEIs began in the ’90s and targeted ADA-SCID and X-SCID, caused by defects in the common gamma chain of IL-2 receptor, and subsequently chronic granulomatous disease and Wiskott–Aldrich syndrome<sup><a href="#ref-196">196</a>–<a href="#ref-202">202</a></sup>. The technique is based on autologous stem cell infusion after <i>in vitro</i> correction of the molecular defect by gene addition, eliminating the risk of GvHD and making it an appealing alternative to HSCT. The original trials were successful in terms of genetic defect correction and clinical benefit, but the gamma-retroviral vectors in use were associated with leukemia or monoclonal expansion, except in the case of ADA-SCID<sup><a href="#ref-196">196</a>,<a href="#ref-197">197</a>,<a href="#ref-203">203</a>–<a href="#ref-206">206</a></sup>. These serious adverse events seem to have been overcome by the introduction of safer self-inactivating lentiviral vectors, and new studies are under way for a number of IEIs, including RAG-SCID, X-linked lymphoproliferative syndrome, and perforin deficiency<sup><a href="#ref-197">197</a></sup>. Whereas the earlier trials were based on gene addition (that is, the introduction by means of a viral vector of the wild-type gene in the host genome), recent approaches have investigated gene editing as a way to correct a molecular defect <i>in situ</i>. CRISPR/Cas9 has become a particularly trending method, especially if paired with the delivery of a donor template (the wild-type cDNA of the gene of interest) via a viral vector that integrates after the natural promotor of the gene to maintain physiological expression and regulation. At the moment, transfection efficiency is still lower with gene editing methods than with gene addition via lentiviral transduction, mainly due to high cell mortality during transfection procedures, and on-target and off-target side effects must be better understood<sup><a href="#ref-196">196</a>,<a href="#ref-197">197</a></sup>. This technique is in a preclinical stage or phase I/II trials in several IEIs, including X-linked SCID, hyper IgM syndrome, CGD, and X-linked agammaglobulinemia, and looks very promising in the context of GOF mutations<sup><a href="#ref-196">196</a>,<a href="#ref-197">197</a>,<a href="#ref-207">207</a>–<a href="#ref-211">211</a></sup>. Moreover, so-called T-cell gene therapy is being studied for the correction of T cell–intrinsic defects with encouraging results, and trials are under way for IPEX, hyper IgM syndrome, X-linked lymphoproliferative disease, Munc 13-4 deficiency, and perforin deficiency<sup><a href="#ref-207">207</a>,<a href="#ref-212">212</a>–<a href="#ref-216">216</a></sup>. Still at a preclinical phase is base editing, a new development in gene editing techniques that would allow the correction of single point mutations without requiring the DNA cleaving step<sup><a href="#ref-217">217</a>,<a href="#ref-218">218</a></sup>. Future studies will need to clarify what the best positioning of gene therapy approaches versus HSCT versus conservative therapy is.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d377e1887>Conclusions</h2><p class="" id=d377e1890>In this review, we have tried to provide a timely overview of recent advances in the diagnosis and treatment of primary immunodeficiencies/IEIs. With rapidly evolving molecular techniques as the leading force, the end of progress is not yet in sight. Indeed, it can be expected that we are on the verge of a further breakthrough of knowledge in primary immunodeficiency.</p><p class="" id=d377e1893>Challenges will lie in making these treatments and diagnostics tools available to as many patients as possible and to tailor them to specific needs. Undoubtedly, primary immunodeficiencies/IEIs as experiments of nature will continue to teach us about the magnificent and still-underestimated complexity of the human immune system.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d377e1899>Abbreviations</h2><p class="" id=d377e1902>AD, autosomal dominant; ADA, adenosine deaminase; APDS, activated phosphoinositide 3-kinase δ syndrome; AR, autosomal recessive; CARD11, caspase recruitment domain family 11; CDG, congenital disorder of glycosylation; CGD, chronic granulomatous disease; CMC, chronic mucocutaneous candidiasis; CNS, central nervous system; CTLA4, cytotoxic T lymphocyte-associated antigen 4; DOCK8, dedicator of cytokinesis 8; EBV, Epstein–Barr virus; FOXP3, forkhead box P3; GOF, gain of function; GvHD, graft-versus-host disease; HLH, hemophagocytic lymphohistiocytosis; HSCT, hematopoietic stem cell transplantation; IEI, inborn error of immunity; IFN, interferon; IL, interleukin; IL6ST, interleukin 6 signal transducer; IPEX, immunodysregulation polyendocrinopathy enteropathy X-linked; JAK, Janus kinase; LOF, loss of function; LRBA, lipopolysaccharide-responsive beige-like anchor; mAb, monoclonal antibody; mTOR, mechanistic target of rapamycin; NF-κB, nuclear factor kappa B; NGS, next-generation sequencing; PGM3, phosphoglucomutase 3; PI3Kδ, phosphoinositide 3-kinase δ; SCID, severe combined immunodeficiency; SLC37A4, solute carrier family 37 member A4; SPINK5, serine protease inhibitor Kazal type 5; STAT, signal transducer and activator of transcription; Th, T helper; TMC, transmembrane channel-like protein; WES, whole exome sequencing; WGS, whole genome sequencing; ZNF341, zinc finger 341</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d377e1909 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d1784>References</h2><div class="section ref-list"><a name=d377e1909 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737232141"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e1916 class=n-a></a>Tangye SG, Al-Herz W, Bousfiha A, <i> et al.</i>: Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. <i>J Clin Immunol.</i> 2020. <a target=xrefwindow id=d377e1924 href="http://www.ncbi.nlm.nih.gov/pubmed/31953710">PubMed Abstract </a> | <a target=xrefwindow id=d377e1927 href="https://doi.org/10.1007/s10875-019-00737-x">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737232141">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d377e1940 class=n-a></a>Delmonte O, Notarangelo L: Targeted Therapy with Biologicals and Small Molecules in Primary Immunodeficiencies. <i>Med Princ Pract.</i> 2020; <b>29</b>(2): 101–112. <a target=xrefwindow id=d377e1948 href="http://www.ncbi.nlm.nih.gov/pubmed/31597133">PubMed Abstract </a> | <a target=xrefwindow id=d377e1951 href="https://doi.org/10.1159/000503997">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d377e1960 class=n-a></a>Martinez-Quiles N, Goldbach-Mansky R: Updates on autoinflammatory diseases. <i>Curr Opin Immunol.</i> 2018; <b>55</b>: 97–105. <a target=xrefwindow id=d377e1968 href="http://www.ncbi.nlm.nih.gov/pubmed/30453204">PubMed Abstract </a> | <a target=xrefwindow id=d377e1971 href="https://doi.org/10.1016/j.coi.2018.09.014">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d377e1980 class=n-a></a>Rodero MP, Crow YJ: Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. <i>J Exp Med.</i> 2016; <b>213</b>(12): 2527–38. <a target=xrefwindow id=d377e1988 href="http://www.ncbi.nlm.nih.gov/pubmed/27821552">PubMed Abstract </a> | <a target=xrefwindow id=d377e1991 href="https://doi.org/10.1084/jem.20161596">Publisher Full Text </a> | <a target=xrefwindow id=d377e1994 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5110029">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d377e2003 class=n-a></a>Castagnoli R, Delmonte OM, Calzoni E, <i> et al.</i>: Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives. <i>Front Pediatr.</i> 2019; <b>7</b>: 295. <a target=xrefwindow id=d377e2014 href="http://www.ncbi.nlm.nih.gov/pubmed/31440487">PubMed Abstract </a> | <a target=xrefwindow id=d377e2017 href="https://doi.org/10.3389/fped.2019.00295">Publisher Full Text </a> | <a target=xrefwindow id=d377e2021 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6694735">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d377e2031 class=n-a></a>Takenouchi T, Kosaki R, Niizuma T, <i> et al.</i>: Macrothrombocytopenia and developmental delay with a <i>de novo CDC42</i> mutation: Yet another locus for thrombocytopenia and developmental delay. <i>Am J Med Genet A.</i> 2015; <b>167A</b>(11): 2822–5. <a target=xrefwindow id=d377e2045 href="http://www.ncbi.nlm.nih.gov/pubmed/26386261">PubMed Abstract </a> | <a target=xrefwindow id=d377e2049 href="https://doi.org/10.1002/ajmg.a.37275">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d377e2058 class=n-a></a>Takenouchi T, Okamoto N, Ida S, <i> et al.</i>: Further evidence of a mutation in <i>CDC42</i> as a cause of a recognizable syndromic form of thrombocytopenia. <i>Am J Med Genet A.</i> 2016; <b>170A</b>(4): 852–5. <a target=xrefwindow id=d377e2072 href="http://www.ncbi.nlm.nih.gov/pubmed/26708094">PubMed Abstract </a> | <a target=xrefwindow id=d377e2076 href="https://doi.org/10.1002/ajmg.a.37526">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d377e2085 class=n-a></a>Motokawa M, Watanabe S, Nakatomi A, <i> et al.</i>: A hot-spot mutation in <i>CDC42</i> (p.Tyr64Cys) and novel phenotypes in the third patient with Takenouchi-Kosaki syndrome. <i>J Hum Genet.</i> 2018; <b>63</b>(3): 387–90. <a target=xrefwindow id=d377e2099 href="http://www.ncbi.nlm.nih.gov/pubmed/29335451">PubMed Abstract </a> | <a target=xrefwindow id=d377e2103 href="https://doi.org/10.1038/s10038-017-0396-5">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d377e2112 class=n-a></a>Gernez Y, de Jesus AA, Alsaleem H, <i> et al.</i>: Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (<i>CDC42</i>) successfully treated with IL-1β inhibition. <i>J Allergy Clin Immunol.</i> 2019; <b>144</b>(4): 1122–1125.e6. <a target=xrefwindow id=d377e2126 href="http://www.ncbi.nlm.nih.gov/pubmed/31271789">PubMed Abstract </a> | <a target=xrefwindow id=d377e2130 href="https://doi.org/10.1016/j.jaci.2019.06.017">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d377e2139 class=n-a></a>Lam MT, Coppola S, Krumbach OHF, <i> et al.</i>: A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. <i>J Exp Med.</i> 2019; <b>216</b>(12): 2778–99. <a target=xrefwindow id=d377e2150 href="http://www.ncbi.nlm.nih.gov/pubmed/31601675">PubMed Abstract </a> | <a target=xrefwindow id=d377e2153 href="https://doi.org/10.1084/jem.20190147">Publisher Full Text </a> | <a target=xrefwindow id=d377e2157 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6888978">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732605168"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2166 class=n-a></a>Martinelli S, Krumbach OHF, Pantaleoni F, <i> et al.</i>: Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes. <i>Am J Hum Genet.</i> 2018; <b>102</b>(2): 309–20. <a target=xrefwindow id=d377e2177 href="http://www.ncbi.nlm.nih.gov/pubmed/29394990">PubMed Abstract </a> | <a target=xrefwindow id=d377e2180 href="https://doi.org/10.1016/j.ajhg.2017.12.015">Publisher Full Text </a> | <a target=xrefwindow id=d377e2184 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5985417">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732605168">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d377e2198 class=n-a></a>Uehara T, Suzuki H, Okamoto N, <i> et al.</i>: Pathogenetic basis of Takenouchi-Kosaki syndrome: Electron microscopy study using platelets in patients and functional studies in a Caenorhabditis elegans model. <i>Sci Rep.</i> 2019; <b>9</b>(1): 4418. <a target=xrefwindow id=d377e2209 href="http://www.ncbi.nlm.nih.gov/pubmed/30872706">PubMed Abstract </a> | <a target=xrefwindow id=d377e2212 href="https://doi.org/10.1038/s41598-019-40988-7">Publisher Full Text </a> | <a target=xrefwindow id=d377e2216 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6418278">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732739900"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2225 class=n-a></a>Zhang SY, Clark NE, Freije CA, <i> et al.</i>: Inborn Errors of RNA Lariat Metabolism in Humans with Brainstem Viral Infection. <i>Cell.</i> 2018; <b>172</b>(5): 952–965.e18. <a target=xrefwindow id=d377e2236 href="http://www.ncbi.nlm.nih.gov/pubmed/29474921">PubMed Abstract </a> | <a target=xrefwindow id=d377e2239 href="https://doi.org/10.1016/j.cell.2018.02.019">Publisher Full Text </a> | <a target=xrefwindow id=d377e2243 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5886375">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732739900">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718283114"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2256 class=n-a></a>Zhou Q, Yang D, Ombrello AK, <i> et al.</i>: Early-onset stroke and vasculopathy associated with mutations in ADA2. <i>N Engl J Med.</i> 2014; <b>370</b>(10): 911–20. <a target=xrefwindow id=d377e2267 href="http://www.ncbi.nlm.nih.gov/pubmed/24552284">PubMed Abstract </a> | <a target=xrefwindow id=d377e2270 href="https://doi.org/10.1056/NEJMoa1307361">Publisher Full Text </a> | <a target=xrefwindow id=d377e2274 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4193683">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718283114">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718283113"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2287 class=n-a></a>Navon Elkan P, Pierce SB, Segel R, <i> et al.</i>: Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. <i>N Engl J Med.</i> 2014; <b>370</b>(10): 921–31. <a target=xrefwindow id=d377e2298 href="http://www.ncbi.nlm.nih.gov/pubmed/24552285">PubMed Abstract </a> | <a target=xrefwindow id=d377e2301 href="https://doi.org/10.1056/NEJMoa1307362">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718283113">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d377e2314 class=n-a></a>Hashem H, Kelly SJ, Ganson NJ, <i> et al.</i>: Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders. <i>Curr Rheumatol Rep.</i> 2017; <b>19</b>(11): 70. <a target=xrefwindow id=d377e2325 href="http://www.ncbi.nlm.nih.gov/pubmed/28983775">PubMed Abstract </a> | <a target=xrefwindow id=d377e2328 href="https://doi.org/10.1007/s11926-017-0699-8">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d377e2337 class=n-a></a>Nanthapisal S, Murphy C, Omoyinmi E, <i> et al.</i>: Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases. <i>Arthritis Rheumatol.</i> 2016; <b>68</b>(9): 2314–22. <a target=xrefwindow id=d377e2348 href="http://www.ncbi.nlm.nih.gov/pubmed/27059682">PubMed Abstract </a> | <a target=xrefwindow id=d377e2351 href="https://doi.org/10.1002/art.39699">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d377e2361 class=n-a></a>Caorsi R, Penco F, Grossi A, <i> et al.</i>: ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(10): 1648–56. <a target=xrefwindow id=d377e2372 href="http://www.ncbi.nlm.nih.gov/pubmed/28522451">PubMed Abstract </a> | <a target=xrefwindow id=d377e2375 href="https://doi.org/10.1136/annrheumdis-2016-210802">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d377e2384 class=n-a></a>Skrabl-Baumgartner A, Plecko B, Schmidt WM, <i> et al.</i>: Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. <i>Pediatr Rheumatol Online J.</i> 2017; <b>15</b>(1): 67. <a target=xrefwindow id=d377e2395 href="http://www.ncbi.nlm.nih.gov/pubmed/28830446">PubMed Abstract </a> | <a target=xrefwindow id=d377e2398 href="https://doi.org/10.1186/s12969-017-0193-x">Publisher Full Text </a> | <a target=xrefwindow id=d377e2402 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5568374">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d377e2411 class=n-a></a>Nihira H, Nakagawa K, Izawa K, <i> et al.</i>: Fever of unknown origin with rashes in early infancy is indicative of adenosine deaminase type 2 deficiency. <i>Scand J Rheumatol.</i> 2017; <b>47</b>(2): 170–2. <a target=xrefwindow id=d377e2422 href="http://www.ncbi.nlm.nih.gov/pubmed/28665179">PubMed Abstract </a> | <a target=xrefwindow id=d377e2425 href="https://doi.org/10.1080/03009742.2017.1324912">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d377e2434 class=n-a></a>Keer N, Hershfield M, Caskey T, <i> et al.</i>: Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. <i>Rheumatology (Oxford).</i> 2016; <b>55</b>(8): 1145–7. <a target=xrefwindow id=d377e2445 href="http://www.ncbi.nlm.nih.gov/pubmed/27069017">PubMed Abstract </a> | <a target=xrefwindow id=d377e2448 href="https://doi.org/10.1093/rheumatology/kew050">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d377e2457 class=n-a></a>Hashem H, Egler R, Dalal J: Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2. <i>J Pediatr Hematol Oncol.</i> 2017; <b>39</b>(5): e293–e296. <a target=xrefwindow id=d377e2465 href="http://www.ncbi.nlm.nih.gov/pubmed/28230570">PubMed Abstract </a> | <a target=xrefwindow id=d377e2468 href="https://doi.org/10.1097/MPH.0000000000000805">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d377e2477 class=n-a></a>Alsultan A, Basher E, Alqanatish J, <i> et al.</i>: Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis. <i>Pediatr Blood Cancer.</i> 2018; <b>65</b>(4). <a target=xrefwindow id=d377e2488 href="http://www.ncbi.nlm.nih.gov/pubmed/29271561">PubMed Abstract </a> | <a target=xrefwindow id=d377e2491 href="https://doi.org/10.1002/pbc.26912">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d377e2501 class=n-a></a>Trotta L, Martelius T, Siitonen T, <i> et al.</i>: ADA2 deficiency: Clonal lymphoproliferation in a subset of patients.. <i>J Allergy Clin Immunol.</i> 2018; <b>141</b>(4): 1534–1537.e8. <a target=xrefwindow id=d377e2512 href="http://www.ncbi.nlm.nih.gov/pubmed/29391253">PubMed Abstract </a> | <a target=xrefwindow id=d377e2515 href="https://doi.org/10.1016/j.jaci.2018.01.012">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d377e2524 class=n-a></a>Michniacki TF, Hannibal M, Ross CW, <i> et al.</i>: Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure. <i>J Clin Immunol.</i> 2018; <b>38</b>(2): 166–73. <a target=xrefwindow id=d377e2535 href="http://www.ncbi.nlm.nih.gov/pubmed/29411230">PubMed Abstract </a> | <a target=xrefwindow id=d377e2538 href="https://doi.org/10.1007/s10875-018-0480-4">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d377e2547 class=n-a></a>Cipe FE, Aydogmus C, Serwas NK, <i> et al.</i>: Novel Mutation in <i>CECR1</i> Leads to Deficiency of ADA2 with Associated Neutropenia. <i>J Clin Immunol.</i> 2018; <b>38</b>(3): 273–7. <a target=xrefwindow id=d377e2561 href="http://www.ncbi.nlm.nih.gov/pubmed/29564582">PubMed Abstract </a> | <a target=xrefwindow id=d377e2565 href="https://doi.org/10.1007/s10875-018-0487-x">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d377e2574 class=n-a></a>Hsu AP, West RR, Calvo KR, <i> et al.</i>: Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. <i>J Allergy Clin Immunol.</i> 2016; <b>138</b>(2): 628–630.e2. <a target=xrefwindow id=d377e2585 href="http://www.ncbi.nlm.nih.gov/pubmed/27130863">PubMed Abstract </a> | <a target=xrefwindow id=d377e2588 href="https://doi.org/10.1016/j.jaci.2016.03.016">Publisher Full Text </a> | <a target=xrefwindow id=d377e2592 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4975951">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d377e2601 class=n-a></a>Elbracht M, Mull M, Wagner N, <i> et al.</i>: Stroke as Initial Manifestation of Adenosine Deaminase 2 Deficiency. <i>Neuropediatrics.</i> 2017; <b>48</b>(2): 111–4. <a target=xrefwindow id=d377e2612 href="http://www.ncbi.nlm.nih.gov/pubmed/28024309">PubMed Abstract </a> | <a target=xrefwindow id=d377e2615 href="https://doi.org/10.1055/s-0036-1597611">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d377e2624 class=n-a></a>Meyts I, Aksentijevich I: Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. <i>J Clin Immunol.</i> 2018; <b>38</b>(5): 569–78. <a target=xrefwindow id=d377e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/29951947">PubMed Abstract </a> | <a target=xrefwindow id=d377e2635 href="https://doi.org/10.1007/s10875-018-0525-8">Publisher Full Text </a> | <a target=xrefwindow id=d377e2638 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6061100">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d377e2648 class=n-a></a>Moens L, Hershfield M, Arts K, <i> et al.</i>: Human adenosine deaminase 2 deficiency: A multi-faceted inborn error of immunity. <i>Immunol Rev.</i> 2019; <b>287</b>(1): 62–72. <a target=xrefwindow id=d377e2659 href="http://www.ncbi.nlm.nih.gov/pubmed/30565235">PubMed Abstract </a> | <a target=xrefwindow id=d377e2662 href="https://doi.org/10.1111/imr.12722">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d377e2671 class=n-a></a>Slade C, Bosco J, Unglik G, <i> et al.</i>: Deficiency in complement factor B. <i>N Engl J Med.</i> 2013; <b>369</b>(17): 1667–9. <a target=xrefwindow id=d377e2682 href="http://www.ncbi.nlm.nih.gov/pubmed/24152280">PubMed Abstract </a> | <a target=xrefwindow id=d377e2685 href="https://doi.org/10.1056/NEJMc1306326">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1058916"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2694 class=n-a></a>Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, <i> et al.</i>: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. <i>Proc Natl Acad Sci U S A.</i> 2007; <b>104</b>(1): 240–5. <a target=xrefwindow id=d377e2705 href="http://www.ncbi.nlm.nih.gov/pubmed/17182750">PubMed Abstract </a> | <a target=xrefwindow id=d377e2708 href="https://doi.org/10.1073/pnas.0603420103">Publisher Full Text </a> | <a target=xrefwindow id=d377e2712 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1765442">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1058916">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718498717"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2725 class=n-a></a>Flanagan SE, Haapaniemi E, Russell MA, <i> et al.</i>: Activating germline mutations in <i>STAT3</i> cause early-onset multi-organ autoimmune disease. <i>Nat Genet.</i> 2014; <b>46</b>(8): 812–4. <a target=xrefwindow id=d377e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/25038750">PubMed Abstract </a> | <a target=xrefwindow id=d377e2743 href="https://doi.org/10.1038/ng.3040">Publisher Full Text </a> | <a target=xrefwindow id=d377e2746 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4129488">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718498717">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1091900"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2759 class=n-a></a>Minegishi Y, Saito M, Tsuchiya S, <i> et al.</i>: Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. <i>Nature.</i> 2007; <b>448</b>(7157): 1058–62. <a target=xrefwindow id=d377e2770 href="http://www.ncbi.nlm.nih.gov/pubmed/17676033">PubMed Abstract </a> | <a target=xrefwindow id=d377e2773 href="https://doi.org/10.1038/nature06096">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1091900">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d377e2786 class=n-a></a>Botto M, Fong KY, So AK, <i> et al.</i>: Molecular basis of polymorphisms of human complement component C3. <i>J Exp Med.</i> 1990; <b>172</b>(4): 1011–7. <a target=xrefwindow id=d377e2797 href="http://www.ncbi.nlm.nih.gov/pubmed/1976733">PubMed Abstract </a> | <a target=xrefwindow id=d377e2800 href="https://doi.org/10.1084/jem.172.4.1011">Publisher Full Text </a> | <a target=xrefwindow id=d377e2804 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2188593">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d377e2814 class=n-a></a>Frémeaux-Bacchi V, Miller EC, Liszewski MK, <i> et al.</i>: Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. <i>Blood.</i> 2008; <b>112</b>(13): 4948–52. <a target=xrefwindow id=d377e2825 href="http://www.ncbi.nlm.nih.gov/pubmed/18796626">PubMed Abstract </a> | <a target=xrefwindow id=d377e2828 href="https://doi.org/10.1182/blood-2008-01-133702">Publisher Full Text </a> | <a target=xrefwindow id=d377e2832 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2597601">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d377e2841 class=n-a></a>Devriendt K, Kim AS, Mathijs G, <i> et al.</i>: Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. <i>Nat Genet.</i> 2001; <b>27</b>(3): 313–7. <a target=xrefwindow id=d377e2852 href="http://www.ncbi.nlm.nih.gov/pubmed/11242115">PubMed Abstract </a> | <a target=xrefwindow id=d377e2855 href="https://doi.org/10.1038/85886">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d377e2864 class=n-a></a>Derry JM, Ochs HD, Francke U: Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. <i>Cell.</i> 1994; <b>78</b>(4): 635–44. <a target=xrefwindow id=d377e2872 href="http://www.ncbi.nlm.nih.gov/pubmed/8069912">PubMed Abstract </a> | <a target=xrefwindow id=d377e2875 href="https://doi.org/10.1016/0092-8674(94)90528-2">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d377e2884 class=n-a></a>Villa A, Notarangelo L, Macchi P, <i> et al.</i>: X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. <i>Nat Genet.</i> 1995; <b>9</b>(4): 414–7. <a target=xrefwindow id=d377e2895 href="http://www.ncbi.nlm.nih.gov/pubmed/7795648">PubMed Abstract </a> | <a target=xrefwindow id=d377e2898 href="https://doi.org/10.1038/ng0495-414">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d377e2907 class=n-a></a>Del Bel KL, Ragotte RJ, Saferali A, <i> et al.</i>: <i>JAK1</i> gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. <i>J Allergy Clin Immunol.</i> 2017; <b>139</b>(6): 2016–2020.e5. <a target=xrefwindow id=d377e2921 href="http://www.ncbi.nlm.nih.gov/pubmed/28111307">PubMed Abstract </a> | <a target=xrefwindow id=d377e2925 href="https://doi.org/10.1016/j.jaci.2016.12.957">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d377e2934 class=n-a></a>Eletto D, Burns SO, Angulo I, <i> et al.</i>: Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. <i>Nat Commun.</i> 2016; <b>7</b>: 13992. <a target=xrefwindow id=d377e2945 href="http://www.ncbi.nlm.nih.gov/pubmed/28008925">PubMed Abstract </a> | <a target=xrefwindow id=d377e2948 href="https://doi.org/10.1038/ncomms13992">Publisher Full Text </a> | <a target=xrefwindow id=d377e2952 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5196432">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d377e2962 class=n-a></a>Lamborn IT, Jing H, Zhang Y, <i> et al.</i>: Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. <i>J Exp Med.</i> 2017; <b>214</b>(7): 1949–72. <a target=xrefwindow id=d377e2973 href="http://www.ncbi.nlm.nih.gov/pubmed/28606988">PubMed Abstract </a> | <a target=xrefwindow id=d377e2976 href="https://doi.org/10.1084/jem.20161759">Publisher Full Text </a> | <a target=xrefwindow id=d377e2980 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5502429">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718333671"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e2989 class=n-a></a>Rice GI, Del Toro Duany Y, Jenkinson EM, <i> et al.</i>: Gain-of-function mutations in <i>IFIH1</i> cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. <i>Nat Genet.</i> 2014; <b>46</b>(5): 503–9. <a target=xrefwindow id=d377e3003 href="http://www.ncbi.nlm.nih.gov/pubmed/24686847">PubMed Abstract </a> | <a target=xrefwindow id=d377e3007 href="https://doi.org/10.1038/ng.2933">Publisher Full Text </a> | <a target=xrefwindow id=d377e3010 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4004585">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718333671">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726084564"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3023 class=n-a></a>Chan AY, Punwani D, Kadlecek TA, <i> et al.</i>: A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70. <i>J Exp Med.</i> 2016; <b>213</b>(2): 155–65. <a target=xrefwindow id=d377e3034 href="http://www.ncbi.nlm.nih.gov/pubmed/26783323">PubMed Abstract </a> | <a target=xrefwindow id=d377e3037 href="https://doi.org/10.1084/jem.20150888">Publisher Full Text </a> | <a target=xrefwindow id=d377e3041 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4749924">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726084564">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d377e3054 class=n-a></a>Arpaia E, Shahar M, Dadi H, <i> et al.</i>: Defective T cell receptor signaling and CD8<sup>+</sup> thymic selection in humans lacking zap-70 kinase. <i>Cell.</i> 1994; <b>76</b>(5): 947–58. <a target=xrefwindow id=d377e3068 href="http://www.ncbi.nlm.nih.gov/pubmed/8124727">PubMed Abstract </a> | <a target=xrefwindow id=d377e3072 href="https://doi.org/10.1016/0092-8674(94)90368-9">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d377e3081 class=n-a></a>Chapgier A, Wynn RF, Jouanguy E, <i> et al.</i>: Human complete Stat-1 deficiency is associated with defective type I and II IFN responses <i>in vitro</i> but immunity to some low virulence viruses <i>in vivo</i>. <i>J Immunol.</i> 2006; <b>176</b>(8): 5078–83. <a target=xrefwindow id=d377e3099 href="http://www.ncbi.nlm.nih.gov/pubmed/16585605">PubMed Abstract </a> | <a target=xrefwindow id=d377e3102 href="https://doi.org/10.4049/jimmunol.176.8.5078">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d377e3111 class=n-a></a>Chapgier A, Kong XF, Boisson-Dupuis S, <i> et al.</i>: A partial form of recessive STAT1 deficiency in humans. <i>J Clin Invest.</i> 2009; <b>119</b>(6): 1502–14. <a target=xrefwindow id=d377e3122 href="http://www.ncbi.nlm.nih.gov/pubmed/19436109">PubMed Abstract </a> | <a target=xrefwindow id=d377e3125 href="https://doi.org/10.1172/JCI37083">Publisher Full Text </a> | <a target=xrefwindow id=d377e3129 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2689115">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1000083"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3139 class=n-a></a>Dupuis S, Dargemont C, Fieschi C, <i> et al.</i>: Impairment of mycobacterial but not viral immunity by a germline human <i>STAT1</i> mutation. <i>Science.</i> 2001; <b>293</b>(5528): 300–3. <a target=xrefwindow id=d377e3153 href="http://www.ncbi.nlm.nih.gov/pubmed/11452125">PubMed Abstract </a> | <a target=xrefwindow id=d377e3157 href="https://doi.org/10.1126/science.1061154">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1000083">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/12516956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3170 class=n-a></a>Liu L, Okada S, Kong XF, <i> et al.</i>: Gain-of-function human <i>STAT1</i> mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. <i>J Exp Med.</i> 2011; <b>208</b>(8): 1635–48. <a target=xrefwindow id=d377e3184 href="http://www.ncbi.nlm.nih.gov/pubmed/21727188">PubMed Abstract </a> | <a target=xrefwindow id=d377e3188 href="https://doi.org/10.1084/jem.20110958">Publisher Full Text </a> | <a target=xrefwindow id=d377e3191 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3149226">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/12516956">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9977956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3204 class=n-a></a>van de Veerdonk FL, Plantinga TS, Hoischen A, <i> et al.</i>: <i>STAT1</i> mutations in autosomal dominant chronic mucocutaneous candidiasis. <i>N Engl J Med.</i> 2011; <b>365</b>(1): 54–61. <a target=xrefwindow id=d377e3218 href="http://www.ncbi.nlm.nih.gov/pubmed/21714643">PubMed Abstract </a> | <a target=xrefwindow id=d377e3222 href="https://doi.org/10.1056/NEJMoa1100102">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9977956">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d377e3235 class=n-a></a>Stepensky P, Keller B, Buchta M, <i> et al.</i>: Deficiency of caspase recruitment domain family, member 11 (CARD11), causes profound combined immunodeficiency in human subjects. <i>J Allergy Clin Immunol.</i> 2013; <b>131</b>(2): 477–85.e1. <a target=xrefwindow id=d377e3246 href="http://www.ncbi.nlm.nih.gov/pubmed/23374270">PubMed Abstract </a> | <a target=xrefwindow id=d377e3249 href="https://doi.org/10.1016/j.jaci.2012.11.050">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d377e3258 class=n-a></a>Greil J, Rausch T, Giese T, <i> et al.</i>: Whole-exome sequencing links caspase recruitment domain 11 (<i>CARD11</i>) inactivation to severe combined immunodeficiency. <i>J Allergy Clin Immunol.</i> 2013; <b>131</b>(5): 1376–83.e3. <a target=xrefwindow id=d377e3272 href="http://www.ncbi.nlm.nih.gov/pubmed/23561803">PubMed Abstract </a> | <a target=xrefwindow id=d377e3276 href="https://doi.org/10.1016/j.jaci.2013.02.012">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d377e3285 class=n-a></a>Dadi H, Jones TA, Merico D, <i> et al.</i>: Combined immunodeficiency and atopy caused by a dominant negative mutation in caspase activation and recruitment domain family member 11 (CARD11). <i>J Allergy Clin Immunol.</i> 2018; <b>141</b>(5): 1818–1830.e2. <a target=xrefwindow id=d377e3296 href="http://www.ncbi.nlm.nih.gov/pubmed/28826773">PubMed Abstract </a> | <a target=xrefwindow id=d377e3299 href="https://doi.org/10.1016/j.jaci.2017.06.047">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727730544"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3309 class=n-a></a>Ma CA, Stinson JR, Zhang Y, <i> et al.</i>: Germline hypomorphic <i>CARD11</i> mutations in severe atopic disease. <i>Nat Genet.</i> 2017; <b>49</b>(8): 1192–201. <a target=xrefwindow id=d377e3323 href="http://www.ncbi.nlm.nih.gov/pubmed/28628108">PubMed Abstract </a> | <a target=xrefwindow id=d377e3327 href="https://doi.org/10.1038/ng.3898">Publisher Full Text </a> | <a target=xrefwindow id=d377e3330 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5664152">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727730544">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d377e3343 class=n-a></a>Snow AL, Xiao W, Stinson JR, <i> et al.</i>: Congenital B cell lymphocytosis explained by novel germline <i>CARD11</i> mutations. <i>J Exp Med.</i> 2012; <b>209</b>(12): 2247–61. <a target=xrefwindow id=d377e3357 href="http://www.ncbi.nlm.nih.gov/pubmed/23129749">PubMed Abstract </a> | <a target=xrefwindow id=d377e3361 href="https://doi.org/10.1084/jem.20120831">Publisher Full Text </a> | <a target=xrefwindow id=d377e3364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3501355">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d377e3373 class=n-a></a>Dupuis S, Jouanguy E, Al-Hajjar S, <i> et al.</i>: Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. <i>Nat Genet.</i> 2003; <b>33</b>(3): 388–91. <a target=xrefwindow id=d377e3384 href="http://www.ncbi.nlm.nih.gov/pubmed/12590259">PubMed Abstract </a> | <a target=xrefwindow id=d377e3387 href="https://doi.org/10.1038/ng1097">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d377e3396 class=n-a></a>Boisson-Dupuis S, Kong XF, Okada S, <i> et al.</i>: Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. <i>Curr Opin Immunol.</i> 2012; <b>24</b>(4): 364–78. <a target=xrefwindow id=d377e3407 href="http://www.ncbi.nlm.nih.gov/pubmed/22651901">PubMed Abstract </a> | <a target=xrefwindow id=d377e3410 href="https://doi.org/10.1016/j.coi.2012.04.011">Publisher Full Text </a> | <a target=xrefwindow id=d377e3414 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3477860">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d377e3423 class=n-a></a>Naviglio S, Soncini E, Vairo D, <i> et al.</i>: Long-Term Survival After Hematopoietic Stem Cell Transplantation for Complete STAT1 Deficiency. <i>J Clin Immunol.</i> 2017; <b>37</b>(7): 701–6. <a target=xrefwindow id=d377e3434 href="http://www.ncbi.nlm.nih.gov/pubmed/28815344">PubMed Abstract </a> | <a target=xrefwindow id=d377e3437 href="https://doi.org/10.1007/s10875-017-0430-6">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d377e3446 class=n-a></a>Kong XF, Ciancanelli M, Al-Hajjar S, <i> et al.</i>: A novel form of human STAT1 deficiency impairing early but not late responses to interferons. <i>Blood.</i> 2010; <b>116</b>(26): 5895–906. <a target=xrefwindow id=d377e3457 href="http://www.ncbi.nlm.nih.gov/pubmed/20841510">PubMed Abstract </a> | <a target=xrefwindow id=d377e3460 href="https://doi.org/10.1182/blood-2010-04-280586">Publisher Full Text </a> | <a target=xrefwindow id=d377e3464 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3031383">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d377e3474 class=n-a></a>Kristensen IA, Veirum JE, Møller BK, <i> et al.</i>: Novel STAT1 alleles in a patient with impaired resistance to mycobacteria. <i>J Clin Immunol.</i> 2011; <b>31</b>(2): 265–71. <a target=xrefwindow id=d377e3485 href="http://www.ncbi.nlm.nih.gov/pubmed/21057861">PubMed Abstract </a> | <a target=xrefwindow id=d377e3488 href="https://doi.org/10.1007/s10875-010-9480-8">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d377e3497 class=n-a></a>Chapgier A, Boisson-Dupuis S, Jouanguy E, <i> et al.</i>: Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease. <i>PLoS Genet.</i> 2006; <b>2</b>(8): e131. <a target=xrefwindow id=d377e3508 href="http://www.ncbi.nlm.nih.gov/pubmed/16934001">PubMed Abstract </a> | <a target=xrefwindow id=d377e3511 href="https://doi.org/10.1371/journal.pgen.0020131">Publisher Full Text </a> | <a target=xrefwindow id=d377e3515 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1550284">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d377e3524 class=n-a></a>Toubiana J, Okada S, Hiller J, <i> et al.</i>: Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. <i>Blood.</i> 2016; <b>127</b>(25): 3154–64. <a target=xrefwindow id=d377e3535 href="http://www.ncbi.nlm.nih.gov/pubmed/27114460">PubMed Abstract </a> | <a target=xrefwindow id=d377e3538 href="https://doi.org/10.1182/blood-2015-11-679902">Publisher Full Text </a> | <a target=xrefwindow id=d377e3542 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4920021">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733896055"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3551 class=n-a></a>Dorjbal B, Stinson JR, Ma CA, <i> et al.</i>: Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. <i>J Allergy Clin Immunol.</i> 2019; <b>143</b>(4): 1482–95. <a target=xrefwindow id=d377e3562 href="http://www.ncbi.nlm.nih.gov/pubmed/30170123">PubMed Abstract </a> | <a target=xrefwindow id=d377e3565 href="https://doi.org/10.1016/j.jaci.2018.08.013">Publisher Full Text </a> | <a target=xrefwindow id=d377e3569 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6395549">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733896055">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d377e3582 class=n-a></a>Brohl AS, Stinson JR, Su HC, <i> et al.</i>: Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis. <i>J Clin Immunol.</i> 2015; <b>35</b>(1): 32–46. <a target=xrefwindow id=d377e3593 href="http://www.ncbi.nlm.nih.gov/pubmed/25352053">PubMed Abstract </a> | <a target=xrefwindow id=d377e3596 href="https://doi.org/10.1007/s10875-014-0106-4">Publisher Full Text </a> | <a target=xrefwindow id=d377e3600 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4466218">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d377e3609 class=n-a></a>Meyts I, Bosch B, Bolze A, <i> et al.</i>: Exome and genome sequencing for inborn errors of immunity. <i>J Allergy Clin Immunol.</i> 2016; <b>138</b>(4): 957–69. <a target=xrefwindow id=d377e3620 href="http://www.ncbi.nlm.nih.gov/pubmed/27720020">PubMed Abstract </a> | <a target=xrefwindow id=d377e3623 href="https://doi.org/10.1016/j.jaci.2016.08.003">Publisher Full Text </a> | <a target=xrefwindow id=d377e3627 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5074686">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d377e3637 class=n-a></a>Vaz-Drago R, Custódio N, Carmo-Fonseca M: Deep intronic mutations and human disease. <i>Hum Genet.</i> 2017; <b>136</b>(9): 1093–111. <a target=xrefwindow id=d377e3645 href="http://www.ncbi.nlm.nih.gov/pubmed/28497172">PubMed Abstract </a> | <a target=xrefwindow id=d377e3648 href="https://doi.org/10.1007/s00439-017-1809-4">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d377e3657 class=n-a></a>Meeths M, Chiang SCC, Wood SM, <i> et al.</i>: Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. <i>Blood.</i> 2011; <b>118</b>(22): 5783–93. <a target=xrefwindow id=d377e3668 href="http://www.ncbi.nlm.nih.gov/pubmed/21931115">PubMed Abstract </a> | <a target=xrefwindow id=d377e3671 href="https://doi.org/10.1182/blood-2011-07-369090">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d377e3680 class=n-a></a>Qian Y, Johnson JA, Connor JA, <i> et al.</i>: The 253-kb inversion and deep intronic mutations in UNC13D are present in North American patients with familial hemophagocytic lymphohistiocytosis 3. <i>Pediatr Blood Cancer.</i> 2014; <b>61</b>(6): 1034–40. <a target=xrefwindow id=d377e3691 href="http://www.ncbi.nlm.nih.gov/pubmed/24470399">PubMed Abstract </a> | <a target=xrefwindow id=d377e3694 href="https://doi.org/10.1002/pbc.24955">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d377e3703 class=n-a></a>Entesarian M, Chiang SCC, Schlums H, <i> et al.</i>: Novel deep intronic and missense UNC13D mutations in familial haemophagocytic lymphohistiocytosis type 3. <i>Br J Haematol.</i> 2013; <b>162</b>(3): 415–8. <a target=xrefwindow id=d377e3714 href="http://www.ncbi.nlm.nih.gov/pubmed/23672263">PubMed Abstract </a> | <a target=xrefwindow id=d377e3717 href="https://doi.org/10.1111/bjh.12371">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d377e3726 class=n-a></a>Seo JY, Song JS, Lee KO, <i> et al.</i>: Founder effects in two predominant intronic mutations of UNC13D, c.118-308C&gt;T and c.754-1G&gt;C underlie the unusual predominance of type 3 familial hemophagocytic lymphohistiocytosis (FHL3) in Korea. <i>Ann Hematol.</i> 2013; <b>92</b>(3): 357–64. <a target=xrefwindow id=d377e3737 href="http://www.ncbi.nlm.nih.gov/pubmed/23180437">PubMed Abstract </a> | <a target=xrefwindow id=d377e3740 href="https://doi.org/10.1007/s00277-012-1628-6">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d377e3749 class=n-a></a>Schulert GS, Zhang M, Husami A, <i> et al.</i>: Brief Report: Novel UNC13D Intronic Variant Disrupting an NF-κB Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Rheumatol.</i> 2018; <b>70</b>(6): 963–70. <a target=xrefwindow id=d377e3760 href="http://www.ncbi.nlm.nih.gov/pubmed/29409136">PubMed Abstract </a> | <a target=xrefwindow id=d377e3763 href="https://doi.org/10.1002/art.40438">Publisher Full Text </a> | <a target=xrefwindow id=d377e3767 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5984660">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d377e3777 class=n-a></a>Butte MJ, Haines C, Bonilla FA, <i> et al.</i>: IL-7 receptor deficient SCID with a unique intronic mutation and post-transplant autoimmunity due to chronic GVHD. <i>Clin Immunol.</i> 2007; <b>125</b>(2): 159–64. <a target=xrefwindow id=d377e3788 href="http://www.ncbi.nlm.nih.gov/pubmed/17827065">PubMed Abstract </a> | <a target=xrefwindow id=d377e3791 href="https://doi.org/10.1016/j.clim.2007.06.007">Publisher Full Text </a> | <a target=xrefwindow id=d377e3795 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2100404">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d377e3804 class=n-a></a>Stepensky P, Keller B, Shamriz O, <i> et al.</i>: Deep intronic mis-splicing mutation in JAK3 gene underlies T−B+NK− severe combined immunodeficiency phenotype. <i>Clin Immunol.</i> 2016; <b>163</b>: 91–5. <a target=xrefwindow id=d377e3815 href="http://www.ncbi.nlm.nih.gov/pubmed/26769277">PubMed Abstract </a> | <a target=xrefwindow id=d377e3818 href="https://doi.org/10.1016/j.clim.2016.01.001">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d377e3827 class=n-a></a>Picard C, Dogniaux S, Chemin K, <i> et al.</i>: Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity. <i>Eur J Immunol.</i> 2009; <b>39</b>(7): 1966–76. <a target=xrefwindow id=d377e3838 href="http://www.ncbi.nlm.nih.gov/pubmed/19548248">PubMed Abstract </a> | <a target=xrefwindow id=d377e3841 href="https://doi.org/10.1002/eji.200939385">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736274360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3850 class=n-a></a>Khourieh J, Rao G, Habib T, <i> et al.</i>: A deep intronic splice mutation of STAT3 underlies hyper IgE syndrome by negative dominance. <i>Proc Natl Acad Sci U S A.</i> 2019; <b>116</b>(33): 16463–72. <a target=xrefwindow id=d377e3861 href="http://www.ncbi.nlm.nih.gov/pubmed/31346092">PubMed Abstract </a> | <a target=xrefwindow id=d377e3864 href="https://doi.org/10.1073/pnas.1901409116">Publisher Full Text </a> | <a target=xrefwindow id=d377e3868 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6697804">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736274360">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734432148"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3881 class=n-a></a>Boisson B, Honda Y, Ajiro M, <i> et al.</i>: Rescue of recurrent deep intronic mutation underlying cell type-dependent quantitative NEMO deficiency. <i>J Clin Invest.</i> 2019; <b>129</b>(2): 583–97. <a target=xrefwindow id=d377e3892 href="http://www.ncbi.nlm.nih.gov/pubmed/30422821">PubMed Abstract </a> | <a target=xrefwindow id=d377e3895 href="https://doi.org/10.1172/JCI124011">Publisher Full Text </a> | <a target=xrefwindow id=d377e3899 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6355244">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734432148">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d377e3912 class=n-a></a>Jørgensen SE, Bøttger P, Kofod-Olsen E, <i> et al.</i>: Ectodermal dysplasia with immunodeficiency caused by a branch-point mutation in <i>IKBKG/NEMO</i>. <i>J Allergy Clin Immunol.</i> 2016; <b>138</b>(6): 1706–1709.e4. <a target=xrefwindow id=d377e3926 href="http://www.ncbi.nlm.nih.gov/pubmed/ 27477329">PubMed Abstract </a> | <a target=xrefwindow id=d377e3930 href="https://doi.org/10.1016/j.jaci.2016.05.030">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726248283"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e3940 class=n-a></a>Starokadomskyy P, Gemelli T, Rios JJ, <i> et al.</i>: DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. <i>Nat Immunol.</i> 2016; <b>17</b>(5): 495–504. <a target=xrefwindow id=d377e3951 href="http://www.ncbi.nlm.nih.gov/pubmed/27019227">PubMed Abstract </a> | <a target=xrefwindow id=d377e3954 href="https://doi.org/10.1038/ni.3409">Publisher Full Text </a> | <a target=xrefwindow id=d377e3958 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4836962">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726248283">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d377e3971 class=n-a></a>Meyts I, Casanova JL: A human inborn error connects the α's. <i>Nat Immunol.</i> 2016; <b>17</b>(5): 472–4. <a target=xrefwindow id=d377e3979 href="http://www.ncbi.nlm.nih.gov/pubmed/27092795">PubMed Abstract </a> | <a target=xrefwindow id=d377e3982 href="https://doi.org/10.1038/ni.3420">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d377e3991 class=n-a></a>Bustamante J, Aksu G, Vogt G, <i> et al.</i>: BCG-osis and tuberculosis in a child with chronic granulomatous disease. <i>J Allergy Clin Immunol.</i> 2007; <b>120</b>(1): 32–8. <a target=xrefwindow id=d377e4002 href="http://www.ncbi.nlm.nih.gov/pubmed/17544093">PubMed Abstract </a> | <a target=xrefwindow id=d377e4005 href="https://doi.org/10.1016/j.jaci.2007.04.034">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d377e4014 class=n-a></a>Rump A, Rösen-Wolff A, Gahr M, <i> et al.</i>: A splice-supporting intronic mutation in the last bp position of a cryptic exon within intron 6 of the <i>CYBB</i> gene induces its incorporation into the mRNA causing chronic granulomatous disease (CGD). <i>Gene.</i> 2006; <b>371</b>(2): 174–81. <a target=xrefwindow id=d377e4028 href="http://www.ncbi.nlm.nih.gov/pubmed/16516412">PubMed Abstract </a> | <a target=xrefwindow id=d377e4032 href="https://doi.org/10.1016/j.gene.2005.11.036">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d377e4041 class=n-a></a>Noack D, Heyworth PG, Newburger PE, <i> et al.</i>: An unusual intronic mutation in the <i>CYBB</i> gene giving rise to chronic granulomatous disease. <i>Biochim Biophys Acta.</i> 2001; <b>1537</b>(2): 125–31. <a target=xrefwindow id=d377e4055 href="http://www.ncbi.nlm.nih.gov/pubmed/11566256">PubMed Abstract </a> | <a target=xrefwindow id=d377e4059 href="https://doi.org/10.1016/s0925-4439(01)00065-5">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d377e4068 class=n-a></a>Cavalieri S, Pozzi E, Gatti RA, <i> et al.</i>: Deep-intronic <i>ATM</i> mutation detected by genomic resequencing and corrected <i>in vitro</i> by antisense morpholino oligonucleotide (AMO). <i>Eur J Hum Genet.</i> 2013; <b>21</b>(7): 774–8. <a target=xrefwindow id=d377e4086 href="http://www.ncbi.nlm.nih.gov/pubmed/23211698">PubMed Abstract </a> | <a target=xrefwindow id=d377e4089 href="https://doi.org/10.1038/ejhg.2012.266">Publisher Full Text </a> | <a target=xrefwindow id=d377e4092 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3722957">Free Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d377e4102 class=n-a></a>Coutinho G, Xie J, Du L, <i> et al.</i>: Functional significance of a deep intronic mutation in the ATM gene and evidence for an alternative exon 28a. <i>Hum Mutat.</i> 2005; <b>25</b>(2): 118–24. <a target=xrefwindow id=d377e4113 href="http://www.ncbi.nlm.nih.gov/pubmed/15643608">PubMed Abstract </a> | <a target=xrefwindow id=d377e4116 href="https://doi.org/10.1002/humu.20170">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d377e4125 class=n-a></a>Lee WI, Torgerson TR, Schumacher MJ, <i> et al.</i>: Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. <i>Blood.</i> 2005; <b>105</b>(5): 1881–90. <a target=xrefwindow id=d377e4136 href="http://www.ncbi.nlm.nih.gov/pubmed/15358621">PubMed Abstract </a> | <a target=xrefwindow id=d377e4139 href="https://doi.org/10.1182/blood-2003-12-4420">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d377e4148 class=n-a></a>Lee H, Huang AY, Wang LK, <i> et al.</i>: Diagnostic utility of transcriptome sequencing for rare Mendelian diseases. <i>Genet Med.</i> 2020; <b>22</b>(3): 490–499. <a target=xrefwindow id=d377e4159 href="http://www.ncbi.nlm.nih.gov/pubmed/31607746">PubMed Abstract </a> | <a target=xrefwindow id=d377e4162 href="https://doi.org/10.1038/s41436-019-0672-1">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735893006"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4171 class=n-a></a>Frésard L, Smail C, Ferraro NM, <i> et al.</i>: Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. <i>Nat Med.</i> 2019; <b>25</b>(6): 911–9. <a target=xrefwindow id=d377e4182 href="http://www.ncbi.nlm.nih.gov/pubmed/31160820">PubMed Abstract </a> | <a target=xrefwindow id=d377e4185 href="https://doi.org/10.1038/s41591-019-0457-8">Publisher Full Text </a> | <a target=xrefwindow id=d377e4189 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6634302">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735893006">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735819934"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4202 class=n-a></a>Zhang SY, Jouanguy E, Zhang Q, <i> et al.</i>: Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism. <i>Curr Opin Immunol.</i> 2019; <b>59</b>: 88–100. <a target=xrefwindow id=d377e4213 href="http://www.ncbi.nlm.nih.gov/pubmed/31121434">PubMed Abstract </a> | <a target=xrefwindow id=d377e4216 href="https://doi.org/10.1016/j.coi.2019.03.008">Publisher Full Text </a> | <a target=xrefwindow id=d377e4220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6774828">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735819934">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d377e4233 class=n-a></a>Riquelme SA, Lozano C, Moustafa AM, <i> et al.</i>: CFTR-PTEN-dependent mitochondrial metabolic dysfunction promotes <i>Pseudomonas aeruginosa</i> airway infection. <i>Sci Transl Med.</i> 2019; <b>11</b>(499): pii: eaav4634. <a target=xrefwindow id=d377e4247 href="http://www.ncbi.nlm.nih.gov/pubmed/31270271">PubMed Abstract </a> | <a target=xrefwindow id=d377e4251 href="https://doi.org/10.1126/scitranslmed.aav4634">Publisher Full Text </a> | <a target=xrefwindow id=d377e4254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6784538">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d377e4264 class=n-a></a>Balázs A, Mall MA: Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway. <i>Pediatr Pulmonol.</i> 2019; <b>54 Suppl 3</b>: S5–S12. <a target=xrefwindow id=d377e4272 href="http://www.ncbi.nlm.nih.gov/pubmed/31715090">PubMed Abstract </a> | <a target=xrefwindow id=d377e4275 href="https://doi.org/10.1002/ppul.24462">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d377e4284 class=n-a></a>Elborn JS: Cystic fibrosis. <i>Lancet.</i> 2016; <b>388</b>(10059): 2519–31. <a target=xrefwindow id=d377e4292 href="http://www.ncbi.nlm.nih.gov/pubmed/27140670">PubMed Abstract </a> | <a target=xrefwindow id=d377e4295 href="https://doi.org/10.1016/S0140-6736(16)00576-6">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727641541"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4304 class=n-a></a>Piel FB, Steinberg MH, Rees DC: Sickle Cell Disease. <i>N Engl J Med.</i> 2017; <b>376</b>(16): 1561–73. <a target=xrefwindow id=d377e4312 href="http://www.ncbi.nlm.nih.gov/pubmed/28423290">PubMed Abstract </a> | <a target=xrefwindow id=d377e4315 href="https://doi.org/10.1056/NEJMra1510865">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727641541">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d377e4328 class=n-a></a>Cannas G, Merazga S, Virot E: Sickle Cell Disease and Infections in High- and Low-Income Countries. <i>Mediterr J Hematol Infect Dis.</i> 2019; <b>11</b>(1): e2019042. <a target=xrefwindow id=d377e4336 href="http://www.ncbi.nlm.nih.gov/pubmed/31308918">PubMed Abstract </a> | <a target=xrefwindow id=d377e4339 href="https://doi.org/10.4084/mjhid.2019.042">Publisher Full Text </a> | <a target=xrefwindow id=d377e4342 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6613623">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1044117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4351 class=n-a></a>Casrouge A, Zhang SY, Eidenschenk C, <i> et al.</i>: Herpes simplex virus encephalitis in human UNC-93B deficiency. <i>Science.</i> 2006; <b>314</b>(5797): 308–12. <a target=xrefwindow id=d377e4362 href="http://www.ncbi.nlm.nih.gov/pubmed/16973841">PubMed Abstract </a> | <a target=xrefwindow id=d377e4365 href="https://doi.org/10.1126/science.1128346">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1044117">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d377e4378 class=n-a></a>Herman M, Ciancanelli M, Ou YH, <i> et al.</i>: Heterozygous <i>TBK1</i> mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. <i>J Exp Med.</i> 2012; <b>209</b>(9): 1567–82. <a target=xrefwindow id=d377e4392 href="http://www.ncbi.nlm.nih.gov/pubmed/22851595">PubMed Abstract </a> | <a target=xrefwindow id=d377e4396 href="https://doi.org/10.1084/jem.20111316">Publisher Full Text </a> | <a target=xrefwindow id=d377e4399 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3428952">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/7278956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4409 class=n-a></a>Pérez de Diego R, Sancho-Shimizu V, Lorenzo L, <i> et al.</i>: Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. <i>Immunity.</i> 2010; <b>33</b>(3): 400–11. <a target=xrefwindow id=d377e4420 href="http://www.ncbi.nlm.nih.gov/pubmed/20832341">PubMed Abstract </a> | <a target=xrefwindow id=d377e4423 href="https://doi.org/10.1016/j.immuni.2010.08.014">Publisher Full Text </a> | <a target=xrefwindow id=d377e4427 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2946444">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/7278956">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d377e4440 class=n-a></a>Sancho-Shimizu V, Pérez de Diego R, Lorenzo L, <i> et al.</i>: Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. <i>J Clin Invest.</i> 2011; <b>121</b>(12): 4889–902. <a target=xrefwindow id=d377e4451 href="http://www.ncbi.nlm.nih.gov/pubmed/22105173">PubMed Abstract </a> | <a target=xrefwindow id=d377e4454 href="https://doi.org/10.1172/JCI59259">Publisher Full Text </a> | <a target=xrefwindow id=d377e4458 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3226004">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1091813"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4467 class=n-a></a>Zhang SY, Jouanguy E, Ugolini S, <i> et al.</i>: TLR3 deficiency in patients with herpes simplex encephalitis. <i>Science.</i> 2007; <b>317</b>(5844): 1522–7. <a target=xrefwindow id=d377e4478 href="http://www.ncbi.nlm.nih.gov/pubmed/17872438">PubMed Abstract </a> | <a target=xrefwindow id=d377e4481 href="https://doi.org/10.1126/science.1139522">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1091813">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13277010"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4494 class=n-a></a>Guo Y, Audry M, Ciancanelli M, <i> et al.</i>: Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. <i>J Exp Med.</i> 2011; <b>208</b>(10): 2083–98. <a target=xrefwindow id=d377e4505 href="http://www.ncbi.nlm.nih.gov/pubmed/21911422">PubMed Abstract </a> | <a target=xrefwindow id=d377e4508 href="https://doi.org/10.1084/jem.20101568">Publisher Full Text </a> | <a target=xrefwindow id=d377e4512 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3182056">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13277010">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d377e4525 class=n-a></a>Andersen LL, Mørk N, Reinert LS, <i> et al.</i>: Functional IRF3 deficiency in a patient with herpes simplex encephalitis. <i>J Exp Med.</i> 2015; <b>212</b>(9): 1371–9. <a target=xrefwindow id=d377e4536 href="http://www.ncbi.nlm.nih.gov/pubmed/26216125">PubMed Abstract </a> | <a target=xrefwindow id=d377e4539 href="https://doi.org/10.1084/jem.20142274">Publisher Full Text </a> | <a target=xrefwindow id=d377e4543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4548062">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d377e4552 class=n-a></a>Ramoz N, Rueda LA, Bouadjar B, <i> et al.</i>: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. <i>Nat Genet.</i> 2002; <b>32</b>(4): 579–81. <a target=xrefwindow id=d377e4563 href="http://www.ncbi.nlm.nih.gov/pubmed/12426567">PubMed Abstract </a> | <a target=xrefwindow id=d377e4566 href="https://doi.org/10.1038/ng1044">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d377e4576 class=n-a></a>Ramoz N, Taïeb A, Rueda LA, <i> et al.</i>: Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. <i>J Invest Dermatol.</i> 2000; <b>114</b>(6): 1148–53. <a target=xrefwindow id=d377e4587 href="http://www.ncbi.nlm.nih.gov/pubmed/10844558">PubMed Abstract </a> | <a target=xrefwindow id=d377e4590 href="https://doi.org/10.1046/j.1523-1747.2000.00996.x">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733752911"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4599 class=n-a></a>de Jong SJ, Créquer A, Matos I, <i> et al.</i>: The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to β-papillomaviruses. <i>J Exp Med.</i> 2018; <b>215</b>(9): 2289–310. <a target=xrefwindow id=d377e4610 href="http://www.ncbi.nlm.nih.gov/pubmed/30068544">PubMed Abstract </a> | <a target=xrefwindow id=d377e4613 href="https://doi.org/10.1084/jem.20170308">Publisher Full Text </a> | <a target=xrefwindow id=d377e4617 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6122964">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733752911">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737540136"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4630 class=n-a></a>Youssefian L, Vahidnezhad H, Mahmoudi H, <i> et al.</i>: Epidermodysplasia Verruciformis: Genetic Heterogeneity and <i>EVER1</i> and <i>EVER2</i> Mutations Revealed by Genome-Wide Analysis. <i>J Invest Dermatol.</i> 2019; <b>139</b>(1): 241–4. <a target=xrefwindow id=d377e4648 href="http://www.ncbi.nlm.nih.gov/pubmed/30036492">PubMed Abstract </a> | <a target=xrefwindow id=d377e4651 href="https://doi.org/10.1016/j.jid.2018.07.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737540136">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d377e4664 class=n-a></a>Lyons JJ, Milner JD: The clinical and mechanistic intersection of primary atopic disorders and inborn errors of growth and metabolism. <i>Immunol Rev.</i> 2019; <b>287</b>(1): 135–44. <a target=xrefwindow id=d377e4672 href="http://www.ncbi.nlm.nih.gov/pubmed/30565252">PubMed Abstract </a> | <a target=xrefwindow id=d377e4675 href="https://doi.org/10.1111/imr.12727">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718085332"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4684 class=n-a></a>Samuelov L, Sarig O, Harmon RM, <i> et al.</i>: Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. <i>Nat Genet.</i> 2013; <b>45</b>(10): 1244–8. <a target=xrefwindow id=d377e4695 href="http://www.ncbi.nlm.nih.gov/pubmed/23974871">PubMed Abstract </a> | <a target=xrefwindow id=d377e4698 href="https://doi.org/10.1038/ng.2739">Publisher Full Text </a> | <a target=xrefwindow id=d377e4702 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3791825">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718085332">F1000 Recommendation</a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d377e4715 class=n-a></a>McAleer MA, Pohler E, Smith FJ, <i> et al.</i>: Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. <i>J Allergy Clin Immunol.</i> 2015; <b>136</b>(5): 1268–76. <a target=xrefwindow id=d377e4726 href="http://www.ncbi.nlm.nih.gov/pubmed/26073755">PubMed Abstract </a> | <a target=xrefwindow id=d377e4729 href="https://doi.org/10.1016/j.jaci.2015.05.002">Publisher Full Text </a> | <a target=xrefwindow id=d377e4733 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4649901">Free Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732037115"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4743 class=n-a></a>Paller AS, Czarnowicki T, Renert-Yuval Y, <i> et al.</i>: The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. <i>J Am Acad Dermatol.</i> 2018; <b>78</b>(3): 498–505.e2. <a target=xrefwindow id=d377e4754 href="http://www.ncbi.nlm.nih.gov/pubmed/29066275">PubMed Abstract </a> | <a target=xrefwindow id=d377e4757 href="https://doi.org/10.1016/j.jaad.2017.10.026">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732037115">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d377e4770 class=n-a></a>Taiber S, Samuelov L, Mohamad J, <i> et al.</i>: SAM syndrome is characterized by extensive phenotypic heterogeneity. <i>Exp Dermatol.</i> 2018; <b>27</b>(7): 787–90. <a target=xrefwindow id=d377e4781 href="http://www.ncbi.nlm.nih.gov/pubmed/29604126">PubMed Abstract </a> | <a target=xrefwindow id=d377e4784 href="https://doi.org/10.1111/exd.13551">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d377e4793 class=n-a></a>Vakkilainen S, Puhakka L, Klemetti P, <i> et al.</i>: Novel DSP Spectrin 6 Region Variant Causes Neonatal Erythroderma, Failure to Thrive, Severe Herpes Simplex Infections and Brain Lesions. <i>Acta Derm Venereol.</i> 2019; <b>99</b>(9): 789–96. <a target=xrefwindow id=d377e4804 href="http://www.ncbi.nlm.nih.gov/pubmed/31037311">PubMed Abstract </a> | <a target=xrefwindow id=d377e4807 href="https://doi.org/10.2340/00015555-3203">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d377e4816 class=n-a></a>Anthony RM, Ravetch JV: A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. <i>J Clin Immunol.</i> 2010; <b>30 Suppl 1</b>: S9–14. <a target=xrefwindow id=d377e4824 href="http://www.ncbi.nlm.nih.gov/pubmed/20480216">PubMed Abstract </a> | <a target=xrefwindow id=d377e4827 href="https://doi.org/10.1007/s10875-010-9405-6">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d377e4836 class=n-a></a>Crespo HJ, Lau JT, Videira PA: Dendritic cells: a spot on sialic Acid. <i>Front Immunol.</i> 2013; <b>4</b>: 491. <a target=xrefwindow id=d377e4844 href="http://www.ncbi.nlm.nih.gov/pubmed/24409183">PubMed Abstract </a> | <a target=xrefwindow id=d377e4847 href="https://doi.org/10.3389/fimmu.2013.00491">Publisher Full Text </a> | <a target=xrefwindow id=d377e4850 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3873530">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d377e4859 class=n-a></a>Priatel JJ, Chui D, Hiraoka N, <i> et al.</i>: The ST3Gal-I sialyltransferase controls CD8<sup>+</sup> T lymphocyte homeostasis by modulating O-glycan biosynthesis. <i>Immunity.</i> 2000; <b>12</b>(3): 273–83. <a target=xrefwindow id=d377e4873 href="http://www.ncbi.nlm.nih.gov/pubmed/10755614">PubMed Abstract </a> | <a target=xrefwindow id=d377e4877 href="https://doi.org/10.1016/s1074-7613(00)80180-6">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d377e4887 class=n-a></a>Stanley P, Guidos CJ: Regulation of Notch signaling during T- and B-cell development by <i>O</i>-fucose glycans. <i>Immunol Rev.</i> 2009; <b>230</b>(1): 201–15. <a target=xrefwindow id=d377e4898 href="http://www.ncbi.nlm.nih.gov/pubmed/19594638">PubMed Abstract </a> | <a target=xrefwindow id=d377e4901 href="https://doi.org/10.1111/j.1600-065X.2009.00791.x">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d377e4910 class=n-a></a>Baum LG, Crocker PR: Glycoimmunology: ignore at your peril!. <i>Immunol Rev.</i> 2009; <b>230</b>(1): 5–8. <a target=xrefwindow id=d377e4918 href="http://www.ncbi.nlm.nih.gov/pubmed/19594625">PubMed Abstract </a> | <a target=xrefwindow id=d377e4921 href="https://doi.org/10.1111/j.1600-065X.2009.00800.x">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d377e4930 class=n-a></a>Barral DC, Brenner MB: CD1 antigen presentation: how it works. <i>Nat Rev Immunol.</i> 2007; <b>7</b>(12): 929–41. <a target=xrefwindow id=d377e4938 href="http://www.ncbi.nlm.nih.gov/pubmed/18037897">PubMed Abstract </a> | <a target=xrefwindow id=d377e4941 href="https://doi.org/10.1038/nri2191">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d377e4950 class=n-a></a>Jensen T, Galli-Stampino L, Mouritsen S, <i> et al.</i>: T cell recognition of Tn-glycosylated peptide antigens. <i>Eur J Immunol.</i> 1996; <b>26</b>(6): 1342–9. <a target=xrefwindow id=d377e4961 href="http://www.ncbi.nlm.nih.gov/pubmed/8647215">PubMed Abstract </a> | <a target=xrefwindow id=d377e4964 href="https://doi.org/10.1002/eji.1830260625">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735840789"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e4973 class=n-a></a>Pascoal C, Francisco R, Ferro T, <i> et al.</i>: CDG and immune response: From bedside to bench and back. <i>J Inherit Metab Dis.</i> 2020; <b>43</b>(1): 90–124. <a target=xrefwindow id=d377e4984 href="http://www.ncbi.nlm.nih.gov/pubmed/31095764">PubMed Abstract </a> | <a target=xrefwindow id=d377e4987 href="https://doi.org/10.1002/jimd.12126">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735840789">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d377e5000 class=n-a></a>Monticelli M, Ferro T, Jaeken J, <i> et al.</i>: Immunological aspects of congenital disorders of glycosylation (CDG): a review. <i>J Inherit Metab Dis.</i> 2016; <b>39</b>(6): 765–80. <a target=xrefwindow id=d377e5011 href="http://www.ncbi.nlm.nih.gov/pubmed/27393411">PubMed Abstract </a> | <a target=xrefwindow id=d377e5014 href="https://doi.org/10.1007/s10545-016-9954-9">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718535360"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5024 class=n-a></a>Boztug K, Järvinen PM, Salzer E, <i> et al.</i>: JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. <i>Nat Genet.</i> 2014; <b>46</b>(9): 1021–7. <a target=xrefwindow id=d377e5035 href="http://www.ncbi.nlm.nih.gov/pubmed/25129144">PubMed Abstract </a> | <a target=xrefwindow id=d377e5038 href="https://doi.org/10.1038/ng.3069">Publisher Full Text </a> | <a target=xrefwindow id=d377e5042 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4829076">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718535360">F1000 Recommendation</a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d377e5055 class=n-a></a>Boztug K, Appaswamy G, Ashikov A, <i> et al.</i>: A syndrome with congenital neutropenia and mutations in <i>G6PC3</i>. <i>N Engl J Med.</i> 2009; <b>360</b>(1): 32–43. <a target=xrefwindow id=d377e5069 href="http://www.ncbi.nlm.nih.gov/pubmed/19118303">PubMed Abstract </a> | <a target=xrefwindow id=d377e5073 href="https://doi.org/10.1056/NEJMoa0805051">Publisher Full Text </a> | <a target=xrefwindow id=d377e5076 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2778311">Free Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d377e5085 class=n-a></a>Lühn K, Wild MK, Eckhardt M, <i> et al.</i>: The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. <i>Nat Genet.</i> 2001; <b>28</b>(1): 69–72. <a target=xrefwindow id=d377e5096 href="http://www.ncbi.nlm.nih.gov/pubmed/11326279">PubMed Abstract </a> | <a target=xrefwindow id=d377e5099 href="https://doi.org/10.1038/ng0501-69">Publisher Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d377e5108 class=n-a></a>Lübke T, Marquardt T, Etzioni A, <i> et al.</i>: Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. <i>Nat Genet.</i> 2001; <b>28</b>(1): 73–6. <a target=xrefwindow id=d377e5119 href="http://www.ncbi.nlm.nih.gov/pubmed/11326280">PubMed Abstract </a> | <a target=xrefwindow id=d377e5122 href="https://doi.org/10.1038/ng0501-73">Publisher Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d377e5131 class=n-a></a>Jun HS, Weinstein DA, Lee YM, <i> et al.</i>: Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. <i>Blood.</i> 2014; <b>123</b>(18): 2843–53. <a target=xrefwindow id=d377e5142 href="http://www.ncbi.nlm.nih.gov/pubmed/24565827">PubMed Abstract </a> | <a target=xrefwindow id=d377e5145 href="https://doi.org/10.1182/blood-2013-05-502435">Publisher Full Text </a> | <a target=xrefwindow id=d377e5149 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4007611">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d377e5158 class=n-a></a>Chou JY, Cho JH, Kim GY, <i> et al.</i>: Molecular biology and gene therapy for glycogen storage disease type Ib. <i>J Inherit Metab Dis.</i> 2018; <b>41</b>(6): 1007–14. <a target=xrefwindow id=d377e5169 href="http://www.ncbi.nlm.nih.gov/pubmed/29663270">PubMed Abstract </a> | <a target=xrefwindow id=d377e5172 href="https://doi.org/10.1007/s10545-018-0180-5">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d377e5182 class=n-a></a>Zhang Y, Yu X, Ichikawa M, <i> et al.</i>: Autosomal recessive phosphoglucomutase 3 (<i>PGM3</i>) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. <i>J Allergy Clin Immunol.</i> 2014; <b>133</b>(5): 1400–1409.e5. <a target=xrefwindow id=d377e5196 href="http://www.ncbi.nlm.nih.gov/pubmed/24589341">PubMed Abstract </a> | <a target=xrefwindow id=d377e5200 href="https://doi.org/10.1016/j.jaci.2014.02.013">Publisher Full Text </a> | <a target=xrefwindow id=d377e5203 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4016982">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736897600"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5212 class=n-a></a>Ravell JC, Matsuda-Lennikov M, Chauvin SD, <i> et al.</i>: Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. <i>J Clin Invest.</i> 2020; <b>130</b>(1): 507–22. <a target=xrefwindow id=d377e5223 href="http://www.ncbi.nlm.nih.gov/pubmed/31714901">PubMed Abstract </a> | <a target=xrefwindow id=d377e5226 href="https://doi.org/10.1172/JCI131116">Publisher Full Text </a> | <a target=xrefwindow id=d377e5230 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6934229">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736897600">F1000 Recommendation</a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735646285"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5243 class=n-a></a>Blommaert E, Péanne R, Cherepanova NA, <i> et al.</i>: Mutations in <i>MAGT1</i> lead to a glycosylation disorder with a variable phenotype. <i>Proc Natl Acad Sci U S A.</i> 2019; <b>116</b>(20): 9865–70. <a target=xrefwindow id=d377e5257 href="http://www.ncbi.nlm.nih.gov/pubmed/31036665">PubMed Abstract </a> | <a target=xrefwindow id=d377e5261 href="https://doi.org/10.1073/pnas.1817815116">Publisher Full Text </a> | <a target=xrefwindow id=d377e5264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6525510">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735646285">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736823714"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5277 class=n-a></a>Cheng HD, Tirosh I, de Haan N, <i> et al.</i>: IgG Fc glycosylation as an axis of humoral immunity in childhood. <i>J Allergy Clin Immunol.</i> 2020; <b>145</b>(2): 710–713.e9. <a target=xrefwindow id=d377e5288 href="http://www.ncbi.nlm.nih.gov/pubmed/31669096">PubMed Abstract </a> | <a target=xrefwindow id=d377e5291 href="https://doi.org/10.1016/j.jaci.2019.10.012">Publisher Full Text </a> | <a target=xrefwindow id=d377e5295 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7010538">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736823714">F1000 Recommendation</a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d377e5308 class=n-a></a>Hennig C, Baumann U, Ilginus C, <i> et al.</i>: Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab. <i>Br J Haematol.</i> 2010; <b>148</b>(3): 445–8. <a target=xrefwindow id=d377e5319 href="http://www.ncbi.nlm.nih.gov/pubmed/19922533">PubMed Abstract </a> | <a target=xrefwindow id=d377e5322 href="https://doi.org/10.1111/j.1365-2141.2009.07987.x">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d377e5331 class=n-a></a>Rao VK, Price S, Perkins K, <i> et al.</i>: Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). <i>Pediatr Blood Cancer.</i> 2009; <b>52</b>(7): 847–52. <a target=xrefwindow id=d377e5342 href="http://www.ncbi.nlm.nih.gov/pubmed/19214977">PubMed Abstract </a> | <a target=xrefwindow id=d377e5345 href="https://doi.org/10.1002/pbc.21965">Publisher Full Text </a> | <a target=xrefwindow id=d377e5349 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2774763">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d377e5359 class=n-a></a>Gobert D, Bussel JB, Cunningham-Rundles C, <i> et al.</i>: Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. <i>Br J Haematol.</i> 2011; <b>155</b>(4): 498–508. <a target=xrefwindow id=d377e5370 href="http://www.ncbi.nlm.nih.gov/pubmed/21981575">PubMed Abstract </a> | <a target=xrefwindow id=d377e5373 href="https://doi.org/10.1111/j.1365-2141.2011.08880.x">Publisher Full Text </a> | <a target=xrefwindow id=d377e5377 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3428031">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d377e5386 class=n-a></a>Naderi beni F, Fattahi F, Mirshafiey A, <i> et al.</i>: Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. <i>Int Immunopharmacol.</i> 2012; <b>12</b>(4): 689–93. <a target=xrefwindow id=d377e5397 href="http://www.ncbi.nlm.nih.gov/pubmed/22330085">PubMed Abstract </a> | <a target=xrefwindow id=d377e5400 href="https://doi.org/10.1016/j.intimp.2012.01.016">Publisher Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a name=d377e5409 class=n-a></a>Alangari AA, Al-Zamil F, Al-Mazrou A, <i> et al.</i>: Treatment of disseminated mycobacterial infection with high-dose IFN-<i>γ</i> in a patient with IL-12R<i>β</i>1 deficiency. <i>Clin Dev Immunol.</i> 2011; <b>2011</b>: 691956. <a target=xrefwindow id=d377e5427 href="http://www.ncbi.nlm.nih.gov/pubmed/21234109">PubMed Abstract </a> | <a target=xrefwindow id=d377e5430 href="https://doi.org/10.1155/2011/691956">Publisher Full Text </a> | <a target=xrefwindow id=d377e5433 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3014684">Free Full Text </a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d377e5442 class=n-a></a>Yong PL, Russo P, Sullivan KE: Use of sirolimus in IPEX and IPEX-like children. <i>J Clin Immunol.</i> 2008; <b>28</b>(5): 581–7. <a target=xrefwindow id=d377e5450 href="http://www.ncbi.nlm.nih.gov/pubmed/18481161">PubMed Abstract </a> | <a target=xrefwindow id=d377e5453 href="https://doi.org/10.1007/s10875-008-9196-1">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718156954"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5462 class=n-a></a>Lucas CL, Kuehn HS, Zhao F, <i> et al.</i>: Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. <i>Nat Immunol.</i> 2014; <b>15</b>(1): 88–97. <a target=xrefwindow id=d377e5473 href="http://www.ncbi.nlm.nih.gov/pubmed/24165795">PubMed Abstract </a> | <a target=xrefwindow id=d377e5476 href="https://doi.org/10.1038/ni.2771">Publisher Full Text </a> | <a target=xrefwindow id=d377e5480 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4209962">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718156954">F1000 Recommendation</a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d377e5493 class=n-a></a>Coulter TI, Chandra A, Bacon CM, <i> et al.</i>: Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. <i>J Allergy Clin Immunol.</i> 2017; <b>139</b>(2): 597–606.e4. <a target=xrefwindow id=d377e5504 href="http://www.ncbi.nlm.nih.gov/pubmed/27555459">PubMed Abstract </a> | <a target=xrefwindow id=d377e5507 href="https://doi.org/10.1016/j.jaci.2016.06.021">Publisher Full Text </a> | <a target=xrefwindow id=d377e5511 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5292996">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718147586"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5521 class=n-a></a>Angulo I, Vadas O, Garcon F, <i> et al.</i>: Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. <i>Science.</i> 2013; <b>342</b>(6160): 866–71. <a target=xrefwindow id=d377e5532 href="http://www.ncbi.nlm.nih.gov/pubmed/24136356">PubMed Abstract </a> | <a target=xrefwindow id=d377e5535 href="https://doi.org/10.1126/science.1243292">Publisher Full Text </a> | <a target=xrefwindow id=d377e5539 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3930011">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718147586">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d377e5552 class=n-a></a>Avery DT, Kane A, Nguyen T, <i> et al.</i>: Germline-activating mutations in <i>PIK3CD</i> compromise B cell development and function. <i>J Exp Med.</i> 2018; <b>215</b>(8): 2073–95. <a target=xrefwindow id=d377e5566 href="http://www.ncbi.nlm.nih.gov/pubmed/30018075">PubMed Abstract </a> | <a target=xrefwindow id=d377e5570 href="https://doi.org/10.1084/jem.20180010">Publisher Full Text </a> | <a target=xrefwindow id=d377e5573 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6080914">Free Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d377e5582 class=n-a></a>Edwards ESJ, Bier J, Cole TS, <i> et al.</i>: Activating <i>PIK3CD</i> mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. <i>J Allergy Clin Immunol.</i> 2019; <b>143</b>(1): 276–291.e6. <a target=xrefwindow id=d377e5596 href="http://www.ncbi.nlm.nih.gov/pubmed/29800648">PubMed Abstract </a> | <a target=xrefwindow id=d377e5600 href="https://doi.org/10.1016/j.jaci.2018.04.030">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735399631"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5609 class=n-a></a>Tangye SG, Bier J, Lau A, <i> et al.</i>: Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in <i>PIK3CD</i>-the Goldilocks' Effect. <i>J Clin Immunol.</i> 2019; <b>39</b>(2): 148–58. <a target=xrefwindow id=d377e5623 href="http://www.ncbi.nlm.nih.gov/pubmed/30911953">PubMed Abstract </a> | <a target=xrefwindow id=d377e5627 href="https://doi.org/10.1007/s10875-019-00612-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735399631">F1000 Recommendation</a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d377e5640 class=n-a></a>Maccari ME, Abolhassani H, Aghamohammadi A, <i> et al.</i>: Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. <i>Front Immunol.</i> 2018; <b>9</b>: 543. <a target=xrefwindow id=d377e5651 href="http://www.ncbi.nlm.nih.gov/pubmed/29599784">PubMed Abstract </a> | <a target=xrefwindow id=d377e5654 href="https://doi.org/10.3389/fimmu.2018.00543">Publisher Full Text </a> | <a target=xrefwindow id=d377e5658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5863269">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731685017"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5667 class=n-a></a>Rao VK, Webster S, Dalm VASH, <i> et al.</i>: Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib. <i>Blood.</i> 2017; <b>130</b>(21): 2307–16. <a target=xrefwindow id=d377e5678 href="http://www.ncbi.nlm.nih.gov/pubmed/28972011">PubMed Abstract </a> | <a target=xrefwindow id=d377e5681 href="https://doi.org/10.1182/blood-2017-08-801191">Publisher Full Text </a> | <a target=xrefwindow id=d377e5685 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5701526">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731685017">F1000 Recommendation</a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d377e5699 class=n-a></a>Hoegenauer K, Soldermann N, Zécri F, <i> et al.</i>: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. <i>ACS Med Chem Lett.</i> 2017; <b>8</b>(9): 975–80. <a target=xrefwindow id=d377e5710 href="http://www.ncbi.nlm.nih.gov/pubmed/28947947">PubMed Abstract </a> | <a target=xrefwindow id=d377e5713 href="https://doi.org/10.1021/acsmedchemlett.7b00293">Publisher Full Text </a> | <a target=xrefwindow id=d377e5717 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5601375">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d377e5726 class=n-a></a>Cahn A, Hamblin JN, Begg M, <i> et al.</i>: Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. <i>Pulm Pharmacol Ther.</i> 2017; <b>46</b>: 69–77. <a target=xrefwindow id=d377e5737 href="http://www.ncbi.nlm.nih.gov/pubmed/28823947">PubMed Abstract </a> | <a target=xrefwindow id=d377e5740 href="https://doi.org/10.1016/j.pupt.2017.08.008">Publisher Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718873012"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5749 class=n-a></a>Kuehn HS, Ouyang W, Lo B, <i> et al.</i>: Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>. <i>Science.</i> 2014; <b>345</b>(6204): 1623–7. <a target=xrefwindow id=d377e5763 href="http://www.ncbi.nlm.nih.gov/pubmed/25213377">PubMed Abstract </a> | <a target=xrefwindow id=d377e5767 href="https://doi.org/10.1126/science.1255904">Publisher Full Text </a> | <a target=xrefwindow id=d377e5770 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4371526">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718873012">F1000 Recommendation</a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d377e5783 class=n-a></a>Schubert D, Bode C, Kenefeck R, <i> et al.</i>: Autosomal dominant immune dysregulation syndrome in humans with <i>CTLA4</i> mutations. <i>Nat Med.</i> 2014; <b>20</b>(12): 1410–6. <a target=xrefwindow id=d377e5797 href="http://www.ncbi.nlm.nih.gov/pubmed/25329329">PubMed Abstract </a> | <a target=xrefwindow id=d377e5801 href="https://doi.org/10.1038/nm.3746">Publisher Full Text </a> | <a target=xrefwindow id=d377e5804 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4668597">Free Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733180435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5813 class=n-a></a>Schwab C, Gabrysch A, Olbrich P, <i> et al.</i>: Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. <i>J Allergy Clin Immunol.</i> 2018; <b>142</b>(6): 1932–46. <a target=xrefwindow id=d377e5824 href="http://www.ncbi.nlm.nih.gov/pubmed/29729943">PubMed Abstract </a> | <a target=xrefwindow id=d377e5827 href="https://doi.org/10.1016/j.jaci.2018.02.055">Publisher Full Text </a> | <a target=xrefwindow id=d377e5831 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6215742">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733180435">F1000 Recommendation</a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d377e5844 class=n-a></a>Lopez-Herrera G, Tampella G, Pan-Hammarström Q, <i> et al.</i>: Deleterious mutations in <i>LRBA</i> are associated with a syndrome of immune deficiency and autoimmunity. <i>Am J Hum Genet.</i> 2012; <b>90</b>(6): 986–1001. <a target=xrefwindow id=d377e5858 href="http://www.ncbi.nlm.nih.gov/pubmed/22608502">PubMed Abstract </a> | <a target=xrefwindow id=d377e5862 href="https://doi.org/10.1016/j.ajhg.2012.04.015">Publisher Full Text </a> | <a target=xrefwindow id=d377e5865 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3370280">Free Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d377e5875 class=n-a></a>Charbonnier LM, Janssen E, Chou J, <i> et al.</i>: Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. <i>J Allergy Clin Immunol.</i> 2015; <b>135</b>(1): 217–27. <a target=xrefwindow id=d377e5886 href="http://www.ncbi.nlm.nih.gov/pubmed/25468195">PubMed Abstract </a> | <a target=xrefwindow id=d377e5889 href="https://doi.org/10.1016/j.jaci.2014.10.019">Publisher Full Text </a> | <a target=xrefwindow id=d377e5893 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4289093">Free Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d377e5902 class=n-a></a>Gámez-Díaz L, August D, Stepensky P, <i> et al.</i>: The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. <i>J Allergy Clin Immunol.</i> 2016; <b>137</b>(1): 223–30. <a target=xrefwindow id=d377e5913 href="http://www.ncbi.nlm.nih.gov/pubmed/26768763">PubMed Abstract </a> | <a target=xrefwindow id=d377e5916 href="https://doi.org/10.1016/j.jaci.2015.09.025">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d377e5925 class=n-a></a>Lee S, Moon JS, Lee CR, <i> et al.</i>: Abatacept alleviates severe autoimmune symptoms in a patient carrying a <i>de novo</i> variant in <i>CTLA-4</i>. <i>J Allergy Clin Immunol.</i> 2016; <b>137</b>(1): 327–30. <a target=xrefwindow id=d377e5943 href="http://www.ncbi.nlm.nih.gov/pubmed/26478010">PubMed Abstract </a> | <a target=xrefwindow id=d377e5946 href="https://doi.org/10.1016/j.jaci.2015.08.036">Publisher Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733846392"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5955 class=n-a></a>van Leeuwen EM, Cuadrado E, Gerrits AM, <i> et al.</i>: Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient. <i>J Clin Immunol.</i> 2018; <b>38</b>(4): 464–7. <a target=xrefwindow id=d377e5966 href="http://www.ncbi.nlm.nih.gov/pubmed/29796761">PubMed Abstract </a> | <a target=xrefwindow id=d377e5969 href="https://doi.org/10.1007/s10875-018-0511-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733846392">F1000 Recommendation</a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725669971"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e5982 class=n-a></a>Lo B, Zhang K, Lu W, <i> et al.</i>: AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. <i>Science.</i> 2015; <b>349</b>(6246): 436–40. <a target=xrefwindow id=d377e5993 href="http://www.ncbi.nlm.nih.gov/pubmed/26206937">PubMed Abstract </a> | <a target=xrefwindow id=d377e5996 href="https://doi.org/10.1126/science.aaa1663">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725669971">F1000 Recommendation</a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/724814019"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6009 class=n-a></a>Milner JD, Vogel TP, Forbes L, <i> et al.</i>: Early-onset lymphoproliferation and autoimmunity caused by germline <i>STAT3</i> gain-of-function mutations. <i>Blood.</i> 2015; <b>125</b>(4): 591–9. <a target=xrefwindow id=d377e6023 href="http://www.ncbi.nlm.nih.gov/pubmed/25359994">PubMed Abstract </a> | <a target=xrefwindow id=d377e6027 href="https://doi.org/10.1182/blood-2014-09-602763">Publisher Full Text </a> | <a target=xrefwindow id=d377e6030 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4304103">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/724814019">F1000 Recommendation</a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d377e6044 class=n-a></a>Haapaniemi EM, Kaustio M, Rajala HL, <i> et al.</i>: Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in <i>STAT3</i>. <i>Blood.</i> 2015; <b>125</b>(4): 639–48. <a target=xrefwindow id=d377e6058 href="http://www.ncbi.nlm.nih.gov/pubmed/25349174">PubMed Abstract </a> | <a target=xrefwindow id=d377e6062 href="https://doi.org/10.1182/blood-2014-04-570101">Publisher Full Text </a> | <a target=xrefwindow id=d377e6065 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4304109">Free Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d377e6074 class=n-a></a>Roskoski R Jr: Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. <i>Pharmacol Res.</i> 2016; <b>111</b>: 784–803. <a target=xrefwindow id=d377e6082 href="http://www.ncbi.nlm.nih.gov/pubmed/27473820">PubMed Abstract </a> | <a target=xrefwindow id=d377e6085 href="https://doi.org/10.1016/j.phrs.2016.07.038">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d377e6094 class=n-a></a>Banerjee S, Biehl A, Gadina M, <i> et al.</i>: JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. <i>Drugs.</i> 2017; <b>77</b>(5): 521–46. <a target=xrefwindow id=d377e6105 href="http://www.ncbi.nlm.nih.gov/pubmed/28255960">PubMed Abstract </a> | <a target=xrefwindow id=d377e6108 href="https://doi.org/10.1007/s40265-017-0701-9">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d377e6117 class=n-a></a>Forbes LR, Vogel TP, Cooper MA, <i> et al.</i>: Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (<i>STAT1</i>) or <i>STAT3</i> mutations. <i>J Allergy Clin Immunol.</i> 2018; <b>142</b>(5): 1665–9. <a target=xrefwindow id=d377e6135 href="http://www.ncbi.nlm.nih.gov/pubmed/30092289">PubMed Abstract </a> | <a target=xrefwindow id=d377e6138 href="https://doi.org/10.1016/j.jaci.2018.07.020">Publisher Full Text </a> | <a target=xrefwindow id=d377e6141 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6322659">Free Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d377e6150 class=n-a></a>Weinacht KG, Charbonnier LM, Alroqi F, <i> et al.</i>: Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (<i>STAT1</i>) gain-of-function mutation. <i>J Allergy Clin Immunol.</i> 2017; <b>139</b>(5): 1629–1640.e2. <a target=xrefwindow id=d377e6164 href="http://www.ncbi.nlm.nih.gov/pubmed/28139313">PubMed Abstract </a> | <a target=xrefwindow id=d377e6168 href="https://doi.org/10.1016/j.jaci.2016.11.022">Publisher Full Text </a> | <a target=xrefwindow id=d377e6171 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5482293">Free Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d377e6180 class=n-a></a>Al Shehri T, Gilmour K, Gothe F, <i> et al.</i>: Novel Gain-of-Function Mutation in <i>Stat1</i> Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib. <i>J Clin Immunol.</i> 2019; <b>39</b>(8): 776–85. <a target=xrefwindow id=d377e6194 href="http://www.ncbi.nlm.nih.gov/pubmed/31512162">PubMed Abstract </a> | <a target=xrefwindow id=d377e6198 href="https://doi.org/10.1007/s10875-019-00687-4">Publisher Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a name=d377e6208 class=n-a></a>Vargas-Hernández A, Mace EM, Zimmerman O, <i> et al.</i>: Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (<i>STAT1</i>) gain-of-function mutations. <i>J Allergy Clin Immunol.</i> 2018; <b>141</b>(6): 2142–2155.e5. <a target=xrefwindow id=d377e6222 href="http://www.ncbi.nlm.nih.gov/pubmed/29111217">PubMed Abstract </a> | <a target=xrefwindow id=d377e6226 href="https://doi.org/10.1016/j.jaci.2017.08.040">Publisher Full Text </a> | <a target=xrefwindow id=d377e6229 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5924437">Free Full Text </a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d377e6238 class=n-a></a>Bloomfield M, Kanderová V, Paračková, <i> et al.</i>: Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation. <i>J Clin Immunol.</i> 2018; <b>38</b>(5): 589–601. <a target=xrefwindow id=d377e6249 href="http://www.ncbi.nlm.nih.gov/pubmed/29934865">PubMed Abstract </a> | <a target=xrefwindow id=d377e6252 href="https://doi.org/10.1007/s10875-018-0519-6">Publisher Full Text </a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725403072"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6261 class=n-a></a>Higgins E, Al Shehri T, McAleer MA, <i> et al.</i>: Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (<i>STAT1</i>) mutation. <i>J Allergy Clin Immunol.</i> 2015; <b>135</b>(2): 551–3. <a target=xrefwindow id=d377e6275 href="http://www.ncbi.nlm.nih.gov/pubmed/25662309">PubMed Abstract </a> | <a target=xrefwindow id=d377e6279 href="https://doi.org/10.1016/j.jaci.2014.12.1867">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725403072">F1000 Recommendation</a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d377e6292 class=n-a></a>Solomon IH, Li H, Benson LA, <i> et al.</i>: Histopathologic Correlates of Familial Hemophagocytic Lymphohistiocytosis Isolated to the Central Nervous System. <i>J Neuropathol Exp Neurol.</i> 2018; <b>77</b>(12): 1079–84. <a target=xrefwindow id=d377e6303 href="http://www.ncbi.nlm.nih.gov/pubmed/30295794">PubMed Abstract </a> | <a target=xrefwindow id=d377e6306 href="https://doi.org/10.1093/jnen/nly094">Publisher Full Text </a> | <a target=xrefwindow id=d377e6310 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6658858">Free Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a name=d377e6319 class=n-a></a>Jordan MB, Allen CE, Weitzman S, <i> et al.</i>: How I treat hemophagocytic lymphohistiocytosis. <i>Blood.</i> 2011; <b>118</b>(15): 4041–52. <a target=xrefwindow id=d377e6330 href="http://www.ncbi.nlm.nih.gov/pubmed/21828139">PubMed Abstract </a> | <a target=xrefwindow id=d377e6333 href="https://doi.org/10.1182/blood-2011-03-278127">Publisher Full Text </a> | <a target=xrefwindow id=d377e6337 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3204727">Free Full Text </a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a name=d377e6346 class=n-a></a>Bergsten E, Horne A, Aricó, <i> et al.</i>: Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. <i>Blood.</i> 2017; <b>130</b>(25): 2728–38. <a target=xrefwindow id=d377e6357 href="http://www.ncbi.nlm.nih.gov/pubmed/28935695">PubMed Abstract </a> | <a target=xrefwindow id=d377e6360 href="https://doi.org/10.1182/blood-2017-06-788349">Publisher Full Text </a> | <a target=xrefwindow id=d377e6364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5785801">Free Full Text </a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a name=d377e6374 class=n-a></a>Marsh RA, Allen CE, McClain KL, <i> et al.</i>: Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(1): 101–9. <a target=xrefwindow id=d377e6385 href="http://www.ncbi.nlm.nih.gov/pubmed/22522603">PubMed Abstract </a> | <a target=xrefwindow id=d377e6388 href="https://doi.org/10.1002/pbc.24188">Publisher Full Text </a> | <a target=xrefwindow id=d377e6392 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3410971">Free Full Text </a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d377e6401 class=n-a></a>Vallurupalli M, Berliner N: Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. <i>Blood.</i> 2019; <b>134</b>(21): 1783–6. <a target=xrefwindow id=d377e6409 href="http://www.ncbi.nlm.nih.gov/pubmed/31537529">PubMed Abstract </a> | <a target=xrefwindow id=d377e6412 href="https://doi.org/10.1182/blood.2019002289">Publisher Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d377e6421 class=n-a></a>Al-Salama ZT: Emapalumab: First Global Approval. <i>Drugs.</i> 2019; <b>79</b>(1): 99–103. <a target=xrefwindow id=d377e6429 href="http://www.ncbi.nlm.nih.gov/pubmed/30623346">PubMed Abstract </a> | <a target=xrefwindow id=d377e6432 href="https://doi.org/10.1007/s40265-018-1046-8">Publisher Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718494006"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6441 class=n-a></a>Liu Y, Jesus AA, Marrero B, <i> et al.</i>: Activated STING in a vascular and pulmonary syndrome. <i>N Engl J Med.</i> 2014; <b>371</b>(6): 507–18. <a target=xrefwindow id=d377e6452 href="http://www.ncbi.nlm.nih.gov/pubmed/25029335">PubMed Abstract </a> | <a target=xrefwindow id=d377e6455 href="https://doi.org/10.1056/NEJMoa1312625">Publisher Full Text </a> | <a target=xrefwindow id=d377e6459 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4174543">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718494006">F1000 Recommendation</a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726109283"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6472 class=n-a></a>Das R, Guan P, Sprague L, <i> et al.</i>: Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. <i>Blood.</i> 2016; <b>127</b>(13): 1666–75. <a target=xrefwindow id=d377e6483 href="http://www.ncbi.nlm.nih.gov/pubmed/26825707">PubMed Abstract </a> | <a target=xrefwindow id=d377e6486 href="https://doi.org/10.1182/blood-2015-12-684399">Publisher Full Text </a> | <a target=xrefwindow id=d377e6490 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4817310">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726109283">F1000 Recommendation</a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d377e6503 class=n-a></a>Vignesh P, Rawat A, Singh S: An Update on the Use of Immunomodulators in Primary Immunodeficiencies. <i>Clin Rev Allergy Immunol.</i> 2017; <b>52</b>(2): 287–303. <a target=xrefwindow id=d377e6511 href="http://www.ncbi.nlm.nih.gov/pubmed/27873163">PubMed Abstract </a> | <a target=xrefwindow id=d377e6514 href="https://doi.org/10.1007/s12016-016-8591-2">Publisher Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d377e6524 class=n-a></a>Broglie L, Pommert L, Rao S, <i> et al.</i>: Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. <i>Blood Adv.</i> 2017; <b>1</b>(19): 1533–6. <a target=xrefwindow id=d377e6535 href="http://www.ncbi.nlm.nih.gov/pubmed/29296794">PubMed Abstract </a> | <a target=xrefwindow id=d377e6538 href="https://doi.org/10.1182/bloodadvances.2017007526">Publisher Full Text </a> | <a target=xrefwindow id=d377e6542 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5728466">Free Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a name=d377e6551 class=n-a></a>Sin JH, Zangardi ML: Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. <i>Hematol Oncol Stem Cell Ther.</i> 2019; <b>12</b>(3): 166–70. <a target=xrefwindow id=d377e6559 href="http://www.ncbi.nlm.nih.gov/pubmed/28834694">PubMed Abstract </a> | <a target=xrefwindow id=d377e6562 href="https://doi.org/10.1016/j.hemonc.2017.07.002">Publisher Full Text </a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733947928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6571 class=n-a></a>Marsh RA, Hebert KM, Keesler D, <i> et al.</i>: Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. <i>J Allergy Clin Immunol.</i> 2018; <b>142</b>(6): 2004–7. <a target=xrefwindow id=d377e6582 href="http://www.ncbi.nlm.nih.gov/pubmed/30170121">PubMed Abstract </a> | <a target=xrefwindow id=d377e6585 href="https://doi.org/10.1016/j.jaci.2018.08.010">Publisher Full Text </a> | <a target=xrefwindow id=d377e6589 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6289686">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733947928">F1000 Recommendation</a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d377e6602 class=n-a></a>Ferrua F, Galimberti S, Courteille V, <i> et al.</i>: Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. <i>J Allergy Clin Immunol.</i> 2019; <b>143</b>(6): 2238–53. <a target=xrefwindow id=d377e6613 href="http://www.ncbi.nlm.nih.gov/pubmed/30660643">PubMed Abstract </a> | <a target=xrefwindow id=d377e6616 href="https://doi.org/10.1016/j.jaci.2018.12.1010">Publisher Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a name=d377e6625 class=n-a></a>Cole T, Pearce MS, Cant AJ, <i> et al.</i>: Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. <i>J Allergy Clin Immunol.</i> 2013; <b>132</b>(5): 1150–5. <a target=xrefwindow id=d377e6636 href="http://www.ncbi.nlm.nih.gov/pubmed/23870668">PubMed Abstract </a> | <a target=xrefwindow id=d377e6639 href="https://doi.org/10.1016/j.jaci.2013.05.031">Publisher Full Text </a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733885700"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6648 class=n-a></a>Haddad E, Logan BR, Griffith LM, <i> et al.</i>: SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood.</i> 2018; <b>132</b>(17): 1737–49. <a target=xrefwindow id=d377e6659 href="http://www.ncbi.nlm.nih.gov/pubmed/30154114">PubMed Abstract </a> | <a target=xrefwindow id=d377e6662 href="https://doi.org/10.1182/blood-2018-03-840702">Publisher Full Text </a> | <a target=xrefwindow id=d377e6666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6202916">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733885700">F1000 Recommendation</a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a name=d377e6680 class=n-a></a>Puck JM: Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. <i>Immunol Rev.</i> 2019; <b>287</b>(1): 241–52. <a target=xrefwindow id=d377e6688 href="http://www.ncbi.nlm.nih.gov/pubmed/30565242">PubMed Abstract </a> | <a target=xrefwindow id=d377e6691 href="https://doi.org/10.1111/imr.12729">Publisher Full Text </a> | <a target=xrefwindow id=d377e6694 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6324582">Free Full Text </a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a name=d377e6703 class=n-a></a>King JR, Hammarström L: Newborn Screening for Primary Immunodeficiency Diseases: History, Current and Future Practice. <i>J Clin Immunol.</i> 2018; <b>38</b>(1): 56–66. <a target=xrefwindow id=d377e6711 href="http://www.ncbi.nlm.nih.gov/pubmed/29116556">PubMed Abstract </a> | <a target=xrefwindow id=d377e6714 href="https://doi.org/10.1007/s10875-017-0455-x">Publisher Full Text </a> | <a target=xrefwindow id=d377e6717 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5742602">Free Full Text </a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a name=d377e6726 class=n-a></a>Heimall J, Logan BR, Cowan MJ, <i> et al.</i>: Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: A PIDTC natural history study. <i>Blood.</i> 2017; <b>130</b>(25): 2718–27. <a target=xrefwindow id=d377e6737 href="http://www.ncbi.nlm.nih.gov/pubmed/29021228">PubMed Abstract </a> | <a target=xrefwindow id=d377e6740 href="https://doi.org/10.1182/blood-2017-05-781849">Publisher Full Text </a> | <a target=xrefwindow id=d377e6744 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5746165">Free Full Text </a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d377e6753 class=n-a></a>Dvorak CC, Puck JM, Wahlstrom JT, <i> et al.</i>: Neurologic event–free survival demonstrates a benefit for SCID patients diagnosed by newborn screening. <i>Blood Adv.</i> 2017; <b>1</b>(20): 1694–8. <a target=xrefwindow id=d377e6764 href="http://www.ncbi.nlm.nih.gov/pubmed/29296816">PubMed Abstract </a> | <a target=xrefwindow id=d377e6767 href="https://doi.org/10.1182/bloodadvances.2017010835">Publisher Full Text </a> | <a target=xrefwindow id=d377e6771 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5728344">Free Full Text </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a name=d377e6780 class=n-a></a>Railey MD, Lokhnygina Y, Buckley RH: Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. <i>J Pediatr.</i> 2009; <b>155</b>(6): 834–840.e1. <a target=xrefwindow id=d377e6788 href="http://www.ncbi.nlm.nih.gov/pubmed/19818451">PubMed Abstract </a> | <a target=xrefwindow id=d377e6791 href="https://doi.org/10.1016/j.jpeds.2009.07.049">Publisher Full Text </a> | <a target=xrefwindow id=d377e6794 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2784223">Free Full Text </a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a name=d377e6803 class=n-a></a>Shaw P, Shizuru J, Hoenig M, <i> et al.</i>: Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants. <i>Front Pediatr.</i> 2019; <b>7</b>: 434. <a target=xrefwindow id=d377e6814 href="http://www.ncbi.nlm.nih.gov/pubmed/31781522">PubMed Abstract </a> | <a target=xrefwindow id=d377e6817 href="https://doi.org/10.3389/fped.2019.00434">Publisher Full Text </a> | <a target=xrefwindow id=d377e6821 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6851055">Free Full Text </a></span></li><li><a name=ref-186 class=n-a></a><span class=label>186. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735980719"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6831 class=n-a></a>George BM, Kao KS, Kwon HS, <i> et al.</i>: Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance. <i>Cell Stem Cell.</i> 2019; <b>25</b>(2): 185–192.e3. <a target=xrefwindow id=d377e6842 href="http://www.ncbi.nlm.nih.gov/pubmed/31204177">PubMed Abstract </a> | <a target=xrefwindow id=d377e6845 href="https://doi.org/10.1016/j.stem.2019.05.018">Publisher Full Text </a> | <a target=xrefwindow id=d377e6849 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6679784">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735980719">F1000 Recommendation</a></span></li><li><a name=ref-187 class=n-a></a><span class=label>187. </span>&nbsp;<span class=citation><a name=d377e6862 class=n-a></a>Straathof KC, Rao K, Eyrich M, <i> et al.</i>: Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: A phase 1/2 study. <i>Lancet.</i> 2009; <b>374</b>(9693): 912–20. <a target=xrefwindow id=d377e6873 href="http://www.ncbi.nlm.nih.gov/pubmed/19729196">PubMed Abstract </a> | <a target=xrefwindow id=d377e6876 href="https://doi.org/10.1016/S0140-6736(09)60945-4">Publisher Full Text </a></span></li><li><a name=ref-188 class=n-a></a><span class=label>188. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726406351"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e6885 class=n-a></a>Palchaudhuri R, Saez B, Hoggatt J, <i> et al.</i>: Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. <i>Nat Biotechnol.</i> 2016; <b>34</b>(7): 738–45. <a target=xrefwindow id=d377e6896 href="http://www.ncbi.nlm.nih.gov/pubmed/27272386">PubMed Abstract </a> | <a target=xrefwindow id=d377e6899 href="https://doi.org/10.1038/nbt.3584">Publisher Full Text </a> | <a target=xrefwindow id=d377e6903 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5179034">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726406351">F1000 Recommendation</a></span></li><li><a name=ref-189 class=n-a></a><span class=label>189. </span>&nbsp;<span class=citation><a name=d377e6916 class=n-a></a>Abadir E, Bryant C, Larsen S, <i> et al.</i>: Targeting the niche: Depleting haemopoietic stem cells with targeted therapy. <i>Bone Marrow Transplant.</i> 2019; <b>54</b>(7): 961–8. <a target=xrefwindow id=d377e6927 href="http://www.ncbi.nlm.nih.gov/pubmed/30664721">PubMed Abstract </a> | <a target=xrefwindow id=d377e6930 href="https://doi.org/10.1038/s41409-019-0445-0">Publisher Full Text </a></span></li><li><a name=ref-190 class=n-a></a><span class=label>190. </span>&nbsp;<span class=citation><a name=d377e6939 class=n-a></a>Vo P, Gooley TA, Rajendran JG, <i> et al.</i>: Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. <i>Haematologica.</i> 2019; pii: haematol.2019.229492. <a target=xrefwindow id=d377e6947 href="http://www.ncbi.nlm.nih.gov/pubmed/31582553">PubMed Abstract </a> | <a target=xrefwindow id=d377e6950 href="https://doi.org/10.3324/haematol.2019.229492">Publisher Full Text </a></span></li><li><a name=ref-191 class=n-a></a><span class=label>191. </span>&nbsp;<span class=citation><a name=d377e6959 class=n-a></a>Orozco JJ, Kenoyer A, Balkin ER, <i> et al.</i>: Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment. <i>Blood.</i> 2016; <b>127</b>(3): 352–9. <a target=xrefwindow id=d377e6970 href="http://www.ncbi.nlm.nih.gov/pubmed/26576864">PubMed Abstract </a> | <a target=xrefwindow id=d377e6973 href="https://doi.org/10.1182/blood-2014-12-617019">Publisher Full Text </a> | <a target=xrefwindow id=d377e6977 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4722286">Free Full Text </a></span></li><li><a name=ref-192 class=n-a></a><span class=label>192. </span>&nbsp;<span class=citation><a name=d377e6987 class=n-a></a>Mawad R, Gooley TA, Rajendran JG, <i> et al.</i>: Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. <i>Biol Blood Marrow Transplant.</i> 2014; <b>20</b>(9): 1363–8. <a target=xrefwindow id=d377e6998 href="http://www.ncbi.nlm.nih.gov/pubmed/24858425">PubMed Abstract </a> | <a target=xrefwindow id=d377e7001 href="https://doi.org/10.1016/j.bbmt.2014.05.014">Publisher Full Text </a> | <a target=xrefwindow id=d377e7005 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4127337">Free Full Text </a></span></li><li><a name=ref-193 class=n-a></a><span class=label>193. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735034391"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7014 class=n-a></a>Czechowicz A, Palchaudhuri R, Scheck A, <i> et al.</i>: Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. <i>Nat Commun.</i> 2019; <b>10</b>(1): 617. <a target=xrefwindow id=d377e7025 href="http://www.ncbi.nlm.nih.gov/pubmed/30728354">PubMed Abstract </a> | <a target=xrefwindow id=d377e7028 href="https://doi.org/10.1038/s41467-018-08201-x">Publisher Full Text </a> | <a target=xrefwindow id=d377e7032 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6365495">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735034391">F1000 Recommendation</a></span></li><li><a name=ref-194 class=n-a></a><span class=label>194. </span>&nbsp;<span class=citation><a name=d377e7045 class=n-a></a>Agarwal R, Dvorak CC, Prohaska S, <i> et al.</i>: Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning. <i>Biol Blood Marrow Transplant.</i> 2019; <b>25</b>(3 Supplement): S92. <a target=xrefwindow id=d377e7056 href="https://doi.org/10.1016/j.bbmt.2018.12.172">Publisher Full Text </a></span></li><li><a name=ref-195 class=n-a></a><span class=label>195. </span>&nbsp;<span class=citation><a name=d377e7065 class=n-a></a>Kwon HS, Logan AC, Chhabra A, <i> et al.</i>: Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. <i>Blood.</i> 2019; <b>133</b>(19): 2104–8. <a target=xrefwindow id=d377e7076 href="http://www.ncbi.nlm.nih.gov/pubmed/30617195">PubMed Abstract </a> | <a target=xrefwindow id=d377e7079 href="https://doi.org/10.1182/blood-2018-06-853879">Publisher Full Text </a> | <a target=xrefwindow id=d377e7083 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6509543">Free Full Text </a></span></li><li><a name=ref-196 class=n-a></a><span class=label>196. </span>&nbsp;<span class=citation><a name=d377e7092 class=n-a></a>Booth C, Romano R, Roncarolo MG, <i> et al.</i>: Gene therapy for primary immunodeficiency. <i>Hum Mol Genet.</i> 2019; <b>28</b>(R1): R15–R23. <a target=xrefwindow id=d377e7103 href="http://www.ncbi.nlm.nih.gov/pubmed/31297531">PubMed Abstract </a> | <a target=xrefwindow id=d377e7106 href="https://doi.org/10.1093/hmg/ddz170">Publisher Full Text </a></span></li><li><a name=ref-197 class=n-a></a><span class=label>197. </span>&nbsp;<span class=citation><a name=d377e7115 class=n-a></a>Staal FJT, Aiuti A, Cavazzana M: Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives. <i>Front Pediatr.</i> 2019; <b>7</b>: 443. <a target=xrefwindow id=d377e7123 href="http://www.ncbi.nlm.nih.gov/pubmed/31737588">PubMed Abstract </a> | <a target=xrefwindow id=d377e7126 href="https://doi.org/10.3389/fped.2019.00443">Publisher Full Text </a> | <a target=xrefwindow id=d377e7129 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6834641">Free Full Text </a></span></li><li><a name=ref-198 class=n-a></a><span class=label>198. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1007603"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7139 class=n-a></a>Aiuti A, Slavin S, Aker M, <i> et al.</i>: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. <i>Science.</i> 2002; <b>296</b>(5577): 2410–3. <a target=xrefwindow id=d377e7150 href="http://www.ncbi.nlm.nih.gov/pubmed/12089448">PubMed Abstract </a> | <a target=xrefwindow id=d377e7153 href="https://doi.org/10.1126/science.1070104">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1007603">F1000 Recommendation</a></span></li><li><a name=ref-199 class=n-a></a><span class=label>199. </span>&nbsp;<span class=citation><a name=d377e7166 class=n-a></a>Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, <i> et al.</i>: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. <i>Science.</i> 2000; <b>288</b>(5466): 669–72. <a target=xrefwindow id=d377e7177 href="http://www.ncbi.nlm.nih.gov/pubmed/10784449">PubMed Abstract </a> | <a target=xrefwindow id=d377e7180 href="https://doi.org/10.1126/science.288.5466.669">Publisher Full Text </a></span></li><li><a name=ref-200 class=n-a></a><span class=label>200. </span>&nbsp;<span class=citation><a name=d377e7189 class=n-a></a>Gaspar HB, Parsley KL, Howe S, <i> et al.</i>: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. <i>Lancet.</i> 2004; <b>364</b>(9452): 2181–7. <a target=xrefwindow id=d377e7200 href="http://www.ncbi.nlm.nih.gov/pubmed/15610804">PubMed Abstract </a> | <a target=xrefwindow id=d377e7203 href="https://doi.org/10.1016/S0140-6736(04)17590-9">Publisher Full Text </a></span></li><li><a name=ref-201 class=n-a></a><span class=label>201. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1014387"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7212 class=n-a></a>Ott MG, Schmidt M, Schwarzwaelder K, <i> et al.</i>: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of <i>MDS1-EVI1</i>, <i>PRDM16</i> or <i>SETBP1</i>. <i>Nat Med.</i> 2006; <b>12</b>(4): 401–9. <a target=xrefwindow id=d377e7233 href="http://www.ncbi.nlm.nih.gov/pubmed/16582916">PubMed Abstract </a> | <a target=xrefwindow id=d377e7236 href="https://doi.org/10.1038/nm1393">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1014387">F1000 Recommendation</a></span></li><li><a name=ref-202 class=n-a></a><span class=label>202. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6643956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7249 class=n-a></a>Boztug K, Schmidt M, Schwarzer A, <i> et al.</i>: Stem-cell gene therapy for the Wiskott-Aldrich syndrome. <i>N Engl J Med.</i> 2010; <b>363</b>(20): 1918–27. <a target=xrefwindow id=d377e7260 href="http://www.ncbi.nlm.nih.gov/pubmed/21067383">PubMed Abstract </a> | <a target=xrefwindow id=d377e7263 href="https://doi.org/10.1056/NEJMoa1003548">Publisher Full Text </a> | <a target=xrefwindow id=d377e7267 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3064520">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6643956">F1000 Recommendation</a></span></li><li><a name=ref-203 class=n-a></a><span class=label>203. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725963022"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7280 class=n-a></a>Hacein-Bey-Abina S, Garrigue A, Wang GP, <i> et al.</i>: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. <i>J Clin Invest.</i> 2008; <b>118</b>(9): 3132–42. <a target=xrefwindow id=d377e7291 href="http://www.ncbi.nlm.nih.gov/pubmed/18688285">PubMed Abstract </a> | <a target=xrefwindow id=d377e7294 href="https://doi.org/10.1172/JCI35700">Publisher Full Text </a> | <a target=xrefwindow id=d377e7298 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2496963">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725963022">F1000 Recommendation</a></span></li><li><a name=ref-204 class=n-a></a><span class=label>204. </span>&nbsp;<span class=citation><a name=d377e7312 class=n-a></a>Howe SJ, Mansour MR, Schwarzwaelder K, <i> et al.</i>: Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. <i>J Clin Invest.</i> 2008; <b>118</b>(9): 3143–50. <a target=xrefwindow id=d377e7323 href="http://www.ncbi.nlm.nih.gov/pubmed/18688286">PubMed Abstract </a> | <a target=xrefwindow id=d377e7326 href="https://doi.org/10.1172/JCI35798">Publisher Full Text </a> | <a target=xrefwindow id=d377e7330 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2496964">Free Full Text </a></span></li><li><a name=ref-205 class=n-a></a><span class=label>205. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718308660"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7339 class=n-a></a>Braun CJ, Boztug K, Paruzynski A, <i> et al.</i>: Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. <i>Sci Transl Med.</i> 2014; <b>6</b>(227): 227ra33. <a target=xrefwindow id=d377e7350 href="http://www.ncbi.nlm.nih.gov/pubmed/24622513">PubMed Abstract </a> | <a target=xrefwindow id=d377e7353 href="https://doi.org/10.1126/scitranslmed.3007280">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718308660">F1000 Recommendation</a></span></li><li><a name=ref-206 class=n-a></a><span class=label>206. </span>&nbsp;<span class=citation><a name=d377e7366 class=n-a></a>Stein S, Ott MG, Schultze-Strasser S, <i> et al.</i>: Genomic instability and myelodysplasia with monosomy 7 consequent to <i>EVI1</i> activation after gene therapy for chronic granulomatous disease. <i>Nat Med.</i> 2010; <b>16</b>(2): 198–204. <a target=xrefwindow id=d377e7380 href="http://www.ncbi.nlm.nih.gov/pubmed/20098431">PubMed Abstract </a> | <a target=xrefwindow id=d377e7384 href="https://doi.org/10.1038/nm.2088">Publisher Full Text </a></span></li><li><a name=ref-207 class=n-a></a><span class=label>207. </span>&nbsp;<span class=citation><a name=d377e7393 class=n-a></a>Hubbard N, Hagin D, Sommer K, <i> et al.</i>: Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. <i>Blood.</i> 2016; <b>127</b>(21): 2513–22. <a target=xrefwindow id=d377e7404 href="http://www.ncbi.nlm.nih.gov/pubmed/26903548">PubMed Abstract </a> | <a target=xrefwindow id=d377e7407 href="https://doi.org/10.1182/blood-2015-11-683235">Publisher Full Text </a></span></li><li><a name=ref-208 class=n-a></a><span class=label>208. </span>&nbsp;<span class=citation><a name=d377e7416 class=n-a></a>Schiroli G, Ferrari S, Conway A, <i> et al.</i>: Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. <i>Sci Transl Med.</i> 2017; <b>9</b>(411): pii: eaan0820. <a target=xrefwindow id=d377e7427 href="http://www.ncbi.nlm.nih.gov/pubmed/29021165">PubMed Abstract </a> | <a target=xrefwindow id=d377e7430 href="https://doi.org/10.1126/scitranslmed.aan0820">Publisher Full Text </a></span></li><li><a name=ref-209 class=n-a></a><span class=label>209. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735525872"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7439 class=n-a></a>Pavel-Dinu M, Wiebking V, Dejene BT, <i> et al.</i>: Gene correction for SCID-X1 in long-term hematopoietic stem cells. <i>Nat Commun.</i> 2019; <b>10</b>(1): 1634. <a target=xrefwindow id=d377e7450 href="http://www.ncbi.nlm.nih.gov/pubmed/30967552">PubMed Abstract </a> | <a target=xrefwindow id=d377e7453 href="https://doi.org/10.1038/s41467-019-09614-y">Publisher Full Text </a> | <a target=xrefwindow id=d377e7457 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6456568">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735525872">F1000 Recommendation</a></span></li><li><a name=ref-210 class=n-a></a><span class=label>210. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726197613"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7471 class=n-a></a>De Ravin SS, Reik A, Liu PQ, <i> et al.</i>: Targeted gene addition in human CD34<sup>+</sup> hematopoietic cells for correction of X-linked chronic granulomatous disease. <i>Nat Biotechnol.</i> 2016; <b>34</b>(4): 424–9. <a target=xrefwindow id=d377e7485 href="http://www.ncbi.nlm.nih.gov/pubmed/26950749">PubMed Abstract </a> | <a target=xrefwindow id=d377e7489 href="https://doi.org/10.1038/nbt.3513">Publisher Full Text </a> | <a target=xrefwindow id=d377e7492 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4824656">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726197613">F1000 Recommendation</a></span></li><li><a name=ref-211 class=n-a></a><span class=label>211. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727200836"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7505 class=n-a></a>De Ravin SS, Li L, Wu X, <i> et al.</i>: CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. <i>Sci Transl Med.</i> 2017; <b>9</b>(372): pii: eaah3480. <a target=xrefwindow id=d377e7516 href="http://www.ncbi.nlm.nih.gov/pubmed/28077679">PubMed Abstract </a> | <a target=xrefwindow id=d377e7519 href="https://doi.org/10.1126/scitranslmed.aah3480">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727200836">F1000 Recommendation</a></span></li><li><a name=ref-212 class=n-a></a><span class=label>212. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733133023"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7532 class=n-a></a>Panchal N, Houghton B, Diez B, <i> et al.</i>: Transfer of gene-corrected T cells corrects humoral and cytotoxic defects in patients with X-linked lymphoproliferative disease. <i>J Allergy Clin Immunol.</i> 2018; <b>142</b>(1): 235–245.e6. <a target=xrefwindow id=d377e7543 href="http://www.ncbi.nlm.nih.gov/pubmed/29705247">PubMed Abstract </a> | <a target=xrefwindow id=d377e7546 href="https://doi.org/10.1016/j.jaci.2018.02.053">Publisher Full Text </a> | <a target=xrefwindow id=d377e7550 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6034012">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733133023">F1000 Recommendation</a></span></li><li><a name=ref-213 class=n-a></a><span class=label>213. </span>&nbsp;<span class=citation><a name=d377e7563 class=n-a></a>Passerini L, Rossi Mel E, Sartirana C, <i> et al.</i>: CD4<sup>+</sup> T cells from IPEX patients convert into functional and stable regulatory T cells by <i>FOXP3</i> gene transfer. <i>Sci Transl Med.</i> 2013; <b>5</b>(215): 215ra174–215ra174. <a target=xrefwindow id=d377e7581 href="http://www.ncbi.nlm.nih.gov/pubmed/24337481">PubMed Abstract </a> | <a target=xrefwindow id=d377e7584 href="https://doi.org/10.1126/scitranslmed.3007320">Publisher Full Text </a></span></li><li><a name=ref-214 class=n-a></a><span class=label>214. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732538483"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7593 class=n-a></a>Ghosh S, Carmo M, Calero-Garcia M, <i> et al.</i>: T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations. <i>J Allergy Clin Immunol.</i> 2018; <b>142</b>(3): 904–913.e3. <a target=xrefwindow id=d377e7604 href="http://www.ncbi.nlm.nih.gov/pubmed/29355678">PubMed Abstract </a> | <a target=xrefwindow id=d377e7607 href="https://doi.org/10.1016/j.jaci.2017.11.050">Publisher Full Text </a> | <a target=xrefwindow id=d377e7611 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6127027">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732538483">F1000 Recommendation</a></span></li><li><a name=ref-215 class=n-a></a><span class=label>215. </span>&nbsp;<span class=citation><a name=d377e7624 class=n-a></a>Soheili T, Rivière J, Ricciardelli I, <i> et al.</i>: Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice. <i>Blood.</i> 2016; <b>128</b>(24): 2859–62. <a target=xrefwindow id=d377e7635 href="http://www.ncbi.nlm.nih.gov/pubmed/27799161">PubMed Abstract </a> | <a target=xrefwindow id=d377e7638 href="https://doi.org/10.1182/blood-2016-07-729871">Publisher Full Text </a></span></li><li><a name=ref-216 class=n-a></a><span class=label>216. </span>&nbsp;<span class=citation><a name=d377e7648 class=n-a></a>Ferreira LMR, Muller YD, Bluestone JA, <i> et al.</i>: Next-generation regulatory T cell therapy. <i>Nat Rev Drug Discov.</i> 2019; <b>18</b>(10): 749–69. <a target=xrefwindow id=d377e7659 href="http://www.ncbi.nlm.nih.gov/pubmed/31541224">PubMed Abstract </a> | <a target=xrefwindow id=d377e7662 href="https://doi.org/10.1038/s41573-019-0041-4">Publisher Full Text </a></span></li><li><a name=ref-217 class=n-a></a><span class=label>217. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732028781"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d377e7671 class=n-a></a>Gaudelli NM, Komor AC, Rees HA, <i> et al.</i>: Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. <i>Nature.</i> 2017; <b>551</b>(7681): 464–71. <a target=xrefwindow id=d377e7682 href="http://www.ncbi.nlm.nih.gov/pubmed/29160308">PubMed Abstract </a> | <a target=xrefwindow id=d377e7685 href="https://doi.org/10.1038/nature24644">Publisher Full Text </a> | <a target=xrefwindow id=d377e7689 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5726555">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732028781">F1000 Recommendation</a></span></li><li><a name=ref-218 class=n-a></a><span class=label>218. </span>&nbsp;<span class=citation><a name=d377e7702 class=n-a></a>Abbasi J: DNA Base Editing Could Reverse Most Disease-Causing Point Mutations. <i>JAMA.</i> 2017; <b>318</b>(22): 2173. <a target=xrefwindow id=d377e7710 href="http://www.ncbi.nlm.nih.gov/pubmed/29234789">PubMed Abstract </a> | <a target=xrefwindow id=d377e7713 href="https://doi.org/10.1001/jama.2017.19063">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-194/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-194/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Inborn Errors of Immunity, Department of Immunology, Microbiology and Transplantation, KU Leuven, Herestraat 49, Leuven, 3000, Belgium<br/> <sup>2</sup> Childhood Immunology, Department of Pediatrics, University Hospitals Leuven, ERN-RITA Core Member, Herestraat 49, Leuven, 3000, Belgium<br/> <p> <div class=margin-bottom> Giorgia Bucciol <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Isabelle Meyts <br/> <span>Roles: </span> Data Curation, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-194/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 19 Mar 2020, 9:194 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.21553.1">https://doi.org/10.12688/f1000research.21553.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Bucciol G and Meyts I. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=23749 data-id=21553 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21553.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-194/v1/pdf?article_uuid=57de6d71-b9c6-4f14-91c5-51ab5b0b2749" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.21553.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bucciol G and Meyts I. Recent advances in primary immunodeficiency: from molecular diagnosis to treatment [version 1; peer review: 3 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):194 (<a href="https://doi.org/10.12688/f1000research.21553.1" target=_blank>https://doi.org/10.12688/f1000research.21553.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=21553 id=mobile-track-article-signin-21553 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21553?target=/articles/9-194/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23749 /> <input name=articleId type=hidden value=21553 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Andrew L Snow</strong>, Department of Pharmacology, Uniformed Services University of the Health Sciences, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Helen C. Su</strong>, Human Immunological Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Trine H. Mogensen</strong>, Department of Clinical Medicine, Aarhus University, Denmark </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 19 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-194/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-194/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=65520-61377></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=65521-61378></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=65519-61376></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-194/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>19 Mar 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Andrew L Snow</strong>, Department of Pharmacology, Uniformed Services University of the Health Sciences, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Helen C. Su</strong>, Human Immunological Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Trine H. Mogensen</strong>, Department of Clinical Medicine, Aarhus University, Denmark </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-194/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-194/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in primary immunodeficiency:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-194/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-194/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-194/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bucciol G and Meyts I');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-194/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-194",
            templates : {
                twitter : "Recent advances in primary immunodeficiency: from molecular diagnosis.... Bucciol G and Meyts I, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-194/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in primary immunodeficiency: from molecular diagnosis to treatment", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in primary immunodeficiency: from molecular diagnosis to treatment", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/21553/23749")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "23749");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "61376": 0,
                           "61377": 0,
                           "61378": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "eb246cc7-5333-445d-8a9a-7ffc81df72f6";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-194.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-194.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-194.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-194.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-194.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>